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Abstract (English) 
Over the last decades, novel therapies against melanoma have allowed for a 
prolonged survival rate of malignant melanoma while not allowing for a cure 
because of its aggressiveness and death resistance. Therefore, adaptation of existing 
and development of innovative therapeutic interventions for melanoma are required. 
One promising option could be discovery of drugs that are able to induce 
programmed cell death in melanoma. Another strategy is to inhibit molecules and 
cell signalling that are relevant for cell death resistance of melanoma to therapies. 
Thus, the detailed understanding of cell death regulation and potential resistance 
mechanisms of melanoma are indispensable. 
IAPs exert their inhibitory effect on cell death through impairing caspase activities 
and ubiquitination targeted proteins. In our study, the negative regulatory role of 
IAPs in CD95L-mediated cell death was confirmed by using IAP antagonist in a 
panel of human melanoma cell lines in vitro. Furthermore, we found that 
CD95L-induced cell death in absence of IAPs in melanoma cells was dominantly 
mediated by caspase-dependent apoptosis but not necroptosis, which suggested the 
resistance of melanoma to the necroptotic signalling. When we analysed expression 
of necroptosis-related proteins, we found that the protein expression of RIPK3 was 
low or absent in melanoma cell lines compared with cultured keratinocytes, primary 
melanocytes and nevus cells, which resulted from absence of RIPK3 mRNA 
expression. Ectopical expression of RIPK3 in melanoma uncovered the 
CD95L-mediated necroptosis which was correlated with MLKL phosphorylation. 
The indispensability of RIPK3 in necroptosis was further confirmed by mutation of 
RIPK3 kinase domain and RIPK3 specific inhibitors. Hypermethylation of RIPK3 
DNA promoter was identified as the reason for RIPK3 absence in melanoma cell 
lines. Restoration of RIPK3 expression was successful via demethylation reagent. 
Unexpectedly, demethylation-mediated RIPK3 reconstitution failed to induce 
necroptosis in treated melanoma cells. 
NF-κB activation mainly as a pro-survival signalling initiates a variety of genes 
induction in melanomas. In our study, NF-κB activation led to expression or 
upregulation of cIAPs and cFLIP which rendered cell death resistance to melanoma. 
Cell death assay results confirmed the negative regulatory role of NF-κB in 
TNF-mediated cell death. Unusually, NF-κB activation resulted in spontaneous cell 
sensitivity to IAP antagonist via promotion of RIPK1-dependent complex formation 
in IKK2 constitutively activated melanomas. 
Our data verified the negatively regulatory effect of IAPs and NF-κB activation on 
cell death in melanoma cells. RIPK3 was also identified as essential link for 
necroptotic cell death in melanomas. Therefore, overcoming cell death resistance by 
antagonizing IAP activity is a promising strategy for melanoma treatment. In 
addition, reconstitution of RIPK3 to induce necroptosis in melanoma is as an 
alternative option for melanoma therapy.   
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Abstract (German) 
Das maligne Melanom ist eine der  aggressivsten Tumorentitäten und gehört zu den 
gefährlichsten Hautkrebsformen. In den letzten Jahrzehnten wurden neue chemo- 
und immuntherapeutische Behandlungen etabliert, die zwar die Überlebensrate von 
Melanompatienten verlängert aber bisher keine Heilung ermöglicht. Daher ist die 
Anpassung bestehender und die Entwicklung neuer innovativer therapeutischer 
Interventionen zur Bekämpfung des Melanoms wichtig und erforderlich. Eine 
vielversprechende Möglichkeit bieten Therapeutika die in der Lage sind, 
apoptotische, nekroptotische und autophagische Zelltodprozesse zu induzieren.. 
Eine andere Strategie beschäftigt sich mit der Inhibition von Zelltod-blockierenden 
Proteinen oder von Signalwegen, die bedeutend sind für Zelltodresistenzen. Durch 
Inhibition dieser Signalwege und Moleküle könnte die Sensitivität gegenüber 
entsprechender Zelltod-induzierenden Therapeutika im Melanom begünstigt werden. 
Die Identifizierung dieser Zelltod-regulierenden Prozesse einschließlich der 
potentiellen Resistenzmechanismen ist für die Entwicklung neuer therapeutischer 
Interventionen unabkömmlich. 
IAPs vermitteln Zelltodresistenzen durch Inhibition von Caspase-Aktivitäten oder 
durch Ubiquitinierungen von entsprechenden Zielproteinen.  In dieser Studie 
wurde die funktionelle Relevanz der IAPs (Inhibitor of apoptosis proteins) bei der 
Todesrezeptor-vermittelten Zelltodregulation in einem Panel von menschlichen 
Melanomzelllinien in vitro untersucht. Des Weiteren fanden wir, dass der 
CD95L-vermittelte Zelltod in Abwesenheit der IAPs in Melanomzellen dominant 
durch Caspase-abhängige Apoptose und nicht durch Nekroptose vermittelt wird, 
wodurch eine Resistenz der Melanomzellen gegenüber nekroptotischer 
Signalgebung identifiziert wurde. Durch Untersuchungen der endogenen 
Expressionen von Proteinen der Nekroptose-Signalkaskade wurde eine substantiell 
niedriges oder abwesendes RIPK3-Expressionniveau auf Protein- und mRNA-Ebene 
in humanen und murinen Melanomzelllinien gefunden, während RIPK3 in 
kultivierten Keratinozyten, primären Melanozyten und Nävuszellen präsent ist. Die 
artifizielle, ektopische Expression von RIPK3 in Melanomzellen demaskierte die 
CD95L-vermittelte Nekroptose, welches mit MLKL-Phosphorylierungen einhergeht. 
Die unabkömmliche Rolle von RIPK3 für die Nekroptose in Melanomzellen wurde 
durch die Überexpression einer Kinase-inaktiven RIPK3-Mutante als auch durch 
chemische RIPK3-spezifische Inhibitoren gezeigt, welche insbesondere die 
MLKL-Phosphorylierung blockiert. Hypermethylierung im RIPK3-Promotor 
wurden als Ursache für die Abwesenheit der RIPK3-mRNA und damit ders RIPK3 
Proteins identifiziert. Die Rekonstitution der RIPK3 Expression in Melanomzellen 
konnte erfolgreich durch demethylierende Reagenzien erzielt werden. Obwohl 
dadurch die Reexpression von RIPK3 erreicht wurde, konnte keine 
CD95L-vermittelte Nekroptose in den behandelten Melanomzellen beobachtet 
werden. 
Ein weiterer wichtiger Untersuchungsschwerpunkt in dieser Arbeit war die 
VIII  Abstract 
Identifizierung der Rolle von NF- B für die Regulation von Proteinen, die in der 
Zelltodregulation im Melanom eine Rolle spielt. Die Aktivierung von NF-κB dient 
als Überlebenssignal und vermittelt Zelltodresistenzen durch verstärkte Expression 
von einer Vielzahl von Proteinen, insbesondere von cIAPs und cFLIP-Proteinen, wie 
wir es in dieser Studie im Melanom zeigen konnten. Die negative Rolle von NF-κB 
im TNF-vermitteltem Zelltod konnte durch Zelltodanalysen bestätigt werden. 
Interessanter Weise und ungewöhnlich werden Melanomzellen mit konstitutiver 
NF-κB-Aktivierung sensitiv gegenüber IAP-Antagonist-vermitteltem Zelltod und 
fördern die Formierung von RIPK1-abhängige Proteinsignalkomplexe.    
Unsere Daten konnten den negative-regulierenden Effekt von IAPs und von NF-κB 
für Zelltodprozesse in Melanomzellen verifizieren. RIPK3 wurde als essentiellen 
Link für den nekroptotischen Zelltod in Melanomzellen identifiziert. Die 
Überwindung von Zelltodresistenzen durch Inhibition von IAP-Aktivitäten stellt 
somit eine vielversprechende Strategie zur Behandlung von Melanomerkrankungen 
dar. Zusätzlich kann die Rekonstitution von RIPK3 in Melanomen zur Induktion von 
nekroptotischen Zelltodprozessen beitragen, welche eine weitere und alternative 
Option für Therapien bei Melanomerkrankungen darstellen kann. 
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1. Introduction 
1.1 Human skin structure and function 
Skin is the largest organ serving as a natural barrier to protect human body from 
exterior injury. According to the location and structural components (Figure 1), 
human skin can be characterized into epidermis (outer), dermis (interior) and 
subcutaneous fat layer (basal, also called fat layer). 
The outer layer of the skin is named as epidermis which is relatively thin and tough 
(Figure 1). Epidermis is further segmented into five stratums, including stratum 
corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum 
basale [1]. The epidermis is mainly composed of keratinocytes (95%), melanocytes, 
Langerhans cells and Merkel cells [2,3]. Keratinocytes(Figure 1), distributed in 
stratum basale act as a barricade to protect the skin from exterior injury and also to 
prevent underlying tissues from dehydration [4]. Melanocytes (Figure 1), also 
scattered in the stratum basale of epidermis, is responsible for melanin production to 
filtrate UV radiation from sunlight, which can result in DNA damages and further 
skin carcinomas, mainly melanoma [5]. In addition, Langerhans cells in epidermis 
are parts of the skin immune system to detect and defend against foreign substances 
[6]. Dermis (Figure 1), lying in the middle tier of skin, can be dissected into the thin 
upper layer adjoining to the epidermis (papillary region) and the thick bottom layer 
extending to the fat layer(reticular region) [2]. 70% percent of the dermis is made up 
of collagen fibres, elastin and proteoglycans to render skin strength, firmness, 
elasticity, and flexibility. Embedded within the fibrous tissue of the dermis is the 
dermal vasculature, including blood vessels, lymphatic vessels, sensory nervous 
endings, sebaceous glands, sweat glands and hair follicles, which are involved in 
supplying nutrients and oxygen for skin, providing protection from injury, sensing 
and reacting to pain, touch, pressure and temperature, and keeping skin moist and 
soft [7,8]. The innermost layer of skin is the subcutaneous fat layer (Figure 1), which 
is essentially composed of adipocytes for accumulating and storing fats. The fat 
stocking in the adipocytes can be transformed into energy biochemically and served 
as pressure cushion to prevent body from outside injury physically [2]. The fat layer 
also offers inner body with thermal insulation to decelerate the heat loss [9]. 
1.2 Human malignant melanoma 
There are three most common types of human skin cancers: basal cell carcinoma 
(BCC), squamous cell carcinoma (SCC) and malignant melanoma. In all of skin 
cancers, malignant melanoma is the most aggressive and fatal form. With the low 
overall 5-year survival rate, incidence of malignant melanoma continues to increase 
worldwide. Melanoma ranks the 19th among the most common human cancer, with 
approximately 232,000 new cases diagnosed in 2012 accounting for 2% the total 
number of cancers [10]. Therefore, better understanding human skin and 
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carcinogenesis of melanoma will help the discovery effective therapies against 
malignant melanoma. 
 
Figure 1 Scheme of human skin. The structure of human skin can be parted into 
epidermis, dermis and subcutaneous fat layer based on their positions and 
components. 
1.2.1 Malignant melanoma cells characteristics 
Cells are the basic unit that arrange tissues and organs in the human body. Normal 
cells divide and develop in a well-regulated manner in order to ensure the organism 
to function properly. While alterations (genetic or epigenetic mutations) in normal 
cells potentially result in uncontrolled and dysregulated growth and carcinogenesis 
as a result (Figure 2). Escape from cell death is one hallmark of cancer cells that is 
critical for malignant transformation and tumour maintenance. 
In terms of malignant melanoma, it usually originates from the abnormal pigment 
melanocytes scattered in the basal layer of the epidermis [11]. Under the normal 
condition, melanocytes produce melanin which is then transferred to neighbouring 
keratinocytes to protect skin from ultraviolet radiation (UV)-caused damage. 
Abnormal melanocytes resulted from mutations initially develop into pigmented 
lesions and further transform into dysplastic nevi [12]. Uncontrollably melanocytes 
of dysplastic nevi lead to an in situ melanoma that is mostly confined to the 
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epidermis, which is referred as radial growth phase (RGP) of melanoma. If the RGR 
melanoma is not found and treated immediately, it acquires the metastatic potential 
during the vertical growth phase (VGP) to invade to dermis and further lung, bone or 
brain [13,14]. Rapid division and impaired ability to undergo programmed cell death 
in response to a wide range of external stimuli allow melanomas a selective 
advantage for progression and metastasis as well as their notorious resistance to 
therapy. Typical features of normal and tumour cells offer us with extensive 
comprehension of melanoma and improvements for melanoma treatments and 
therapies without injuring normal cells. 
  
Figure 2 Transformation of normal to malignant cells during uncontrolled cell 
division. When normal cells divided and proliferated in a dysregulated manner, they 
develop into a tumour and metastasize to other organs when tumour cells moved 
with the blood stream. 
1.2.2 Risk factors for melanoma 
Environmental factors Sun exposure, as the main source of UV rays, is the major 
environmental risk factor for melanoma. UVB (280-320 nm) is proposed to be the 
most carcinogenic waveband, which can be absorbed by nucleic acids and proteins 
respectively. UVB radiation mainly leads to C-T or CC-TT transitions and minor 
C-A and G-T transversions as genetic mutations. In addition, DNA strand breaks 
resulted from UV radiation are also considered to be involved in the development of 
melanoma [15,16]. In addition to UV rays exposure, contact with environmental 
carcinogenetic chemicals, including polycyclic aromatic hydrocarbons, benzene, 
polychlorinated biphenyls and chromium, is able to induce melanoma. Production of 
reactive oxygen species (ROS), endocrine disruption and immune supress are also 
regarded as the potential inducer for melanoma [17-19]. 
Host factors refer to pigmentation characteristics of nevi, eyes, skin, hair colours 
and also the ability to tan and propensity to burn on individual basis. An analysis of 
10 cases controlled studies supported that both fair skin and degree of freckling were 
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associated with increased risk of developing melanoma [20,21]. In brief, incidences 
of melanoma are reversely correlated with extent of skin pigmentation. 
Germline genetic factors Familial history of melanoma is an alternative useful 
predictor for melanoma incidence. Sharing the certain germline genetic alterations is 
the main reason for the occurrence of melanoma in a family setting. Familial genetic 
linkage studies have identiﬁed CDKN2A and CDK4 as high-penetrance susceptibility 
genes for melanoma. Germline mutations of these genes render an increasing risk of 
melanoma occurrences [22-25]. With the development of gene screening techniques, 
the discovery germline genetic mutations of melanoma will help the early prediction 
and effective treatment for melanoma. 
1.2.3 Therapy option for malignant melanoma  
Surgery As the primary treatment for melanoma, wide excision is applied to remove 
melanoma lesions. In addition, if the result of lymph node biopsy is positive, lymph 
node dissection is executed in some cases. 
Radiation therapy refers as application of rays of high energy, including X-rays, 
gamma-rays and charged particles to kill melanoma cells via DNA damage mediated 
cell death. Radiation therapy is often used as an adjuvant treatment for melanoma 
post-surgery to get rid of the remaining tumour cells [26,27]. 
Chemotherapy The main clinical chemotherapy reagents for melanoma can be 
characterized into mitosis inhibitors (paclitaxel), alkylating-like agents (cisplatin, 
carboplatin) and alkylating agents (dacarbazine, temozolomide). Chemotherapeutic 
agents exert anti-tumour function through inducing DNA damage, interfering with 
cell cycle and inducing cell death as consequences [28]. 
Immunotherapy The primary objective of immunotherapy is to increase activity of 
immune system to destroy tumour cells by cytokines (Interleukin-2 and Interferon-α) 
[29,30]. With the discovery of cancer-related antigens and their inhibitory effect on 
T-lymphocytes to render melanoma cells ability to escape from adaptive immune 
surveillance [31,32], monoclonal antibodies (PD-1 and CTLA-4) are designed to 
attach to specific proteins of cancer cells allow the immune system itself to destroy 
the cancer cells. Immunotherapy because of its highly specificity, is a promising 
strategy to boost immune system response against melanoma cells [33]. 
Targeted Therapy Increasing understanding of molecules driving melanoma has 
allowed considerably novel therapeutic options. Approximate 50% melanoma 
patients possess BRAF mutation (mainly V600E and V600K) which leads to 
constitutive activation of MAPK signalling pathway [34,35]. Selective BRAF 
inhibitors (Vemurafenib and Dabrafenib) have been shown to adjourn melanoma 
progression in patients identified BRAFV600 mutation [36,37]. Encouragingly, 
increasing evidences have demonstrated that concomitant administration of BRAF 
and MEK inhibitors (Trametinib and Selumetinib) prolong progression-free survival, 
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and consequently increase the overall survival rate of melanoma patients [38]. 
Discovery of targeted inhibitors represents an alternative promising strategy for 
melanoma treatment. Also the activation of extrinsic or intrinsic cell death signalling 
pathways by e.g. death ligands or Bcl-2 antagonists can be a strategy for melanoma 
treatment. 
1.3 Programmed cell death  
The conception of programmed cell death was firstly proposed in 1965 to describe 
the death process as a biological planned program in muscles cells of large American 
silkmoths [39]. Multicellular organisms have evolved a self-demise machinery to 
eliminate the damaged, infected, and unwanted cells to assure the whole body can 
better survive. Continuous studies of programmed cell death (PCD) along with the 
development of model organisms and technologies have allowed a better 
understanding of the fundamental process related with mammalian development and 
various diseases.  
1.3.1 Apoptosis 
Apoptosis is a well-regulated cell suicide program that comes in force from early 
embryonic development and continues in the adult life. Apoptosis is thus essential to 
maintain normal body homeostasis, defence against pathogen infection and 
genotoxic stress. Disruption of this native regulatory mechanism of cells leads to 
uncontrolled growth and a wide variety of human diseases including acquired 
immune deficiency disease (AIDS), neurodegenerative disorders, autoimmune 
diseases, stroke, and cancers. Furthermore, understanding of programmed cell death 
has reinforced the development of new therapeutic strategies against human diseases 
[40-43]. 
Apoptosis manifests with cell shrinkage, chromatin condensation, plasma membrane 
blebbing, and finally breakdown of cells into small membrane-bound vesicles 
named as apoptotic bodies. The apoptotic bodies are quickly removed through 
phagocytosis by macrophages, parenchymal cells or neighbouring cells [44]. 
Apoptosis also characterizes with biochemical features including caspases cascade 
activation, DNA breakdown, phosphatidylserine externalization and protein 
cleavage [45]. The dissemination of apoptosis is tightly regulated by two 
well-understood signal transduction pathways, the intrinsic pathway (also known as 
the mitochondrial mediated pathway) and the extrinsic pathway (also known as the 
death receptor mediated pathway). These two pathways converge at the point of 
caspases activation. 
1.3.1.1 Caspases 
As the core for apoptosis initiation, caspases (cysteine aspartate-specific proteases), 
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a group of intracellular cysteine proteases, utilize a catalytic cysteine to cleave their 
peptide substrates after aspartate specific residues. Human caspases are functionally 
categorized into apoptotic caspases (caspase 2, 3, 6, 7, 8, 9, 10) and inflammatory 
caspases (caspase 1, 4, 5, 12). And the apoptotic caspases can be further classified 
into initiator caspases (caspase 2, 8, 9, 10) and effector caspases (caspase 3, 6, 7) 
according to their entry points into the apoptotic cascade [46,47].  
Similar with most proteolytic enzymes, caspases initially reside as inactive 
zymogens known as procaspases, which are triggered into mature active form upon 
stimulation. During the process of apoptosis, the procaspase is cleaved into a small 
subunit and a large subunit through proteolysis. These two cleaved subunits further 
pattern into a heterotetramer as the active form of caspase. 
The inactive initiator caspases are composed of an N-terminal prodomain and a 
catalytic domain (a large and a small subunit linked by a inter subunit). The 
prodomain, serving as an adaptor domain for protein interaction, can be 
characterised into a caspase activation and recruitment domain (CARD, caspase-1, 2, 
4, 5, and 9) and a death effector domain (DED, caspase-8, 10). During the maturation, 
the prodomain is removed and the inter subunit loop forms an active heterotetramer. 
The active initiator caspases cleave inactive effector caspases into the large and 
small subunits resulting in two active sites of the executioner caspase dimer. 
Functional mature effector caspase subsequently coordinate their activities to 
demolish key structural proteins and activate other enzymes to induce apoptosis 
[48-50]. 
The synthetic caspase inhibitors are as well useful tools for analysis of caspase 
activity in cell death process. Active-site inhibitors as one kind of caspase inhibitors 
(such as zVAD-fmk, Q-VD (OMe)-OPh, VX-765) are designed based upon the 
binding and cleaving sites of caspase substrates [51].  
1.3.1.2 The extrinsic apoptosis pathway 
The extrinsic pathway is often described as receptor mediated pathway in which 
extracellular ligands bind to specific transmembrane death receptors and 
subsequently induce cell death [21, 22]. Death receptors belong to the tumour 
necrosis factor receptor superfamily (TNFRSF) with a broad range of biological 
activities in regulating cell death and immune response. All members in the TNF 
receptor super family are characterized with the extracellular cysteine rich domains 
(CRDs) which are responsible for recognition of ligands with specificity. Ligation of 
death receptors, including TNFR1, Fas (CD95) or DR4/5 (TRAIL1/2) receptors with 
corresponding ligands, leads to trimerization of receptors and further recruitment of 
cytosolic adaptor proteins through hydrophilic interaction mediated via the 
conserved intracellular death domains (Figure 3) [52]. Adaptor proteins, 
Fas-associated protein with death domain (FADD) and TNF receptor-associated 
death domain (TRADD), enable the cell death signalling transduce from the exterior 
stimuli to the interior signalling cascade via homotypic proteins interactions [53,54]. 
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In CD95L-induced apoptosis, FADD is preassembled to Fas and in turn recruits 
procaspases (caspase 8, 10) through their homotypic DED-DED (death effector 
domain) interaction and form the death inducing signalling complex (DISC) (Figure 
3) [55]. DISC thereby elevates the local amount of inactive procaspases 8 and 
subsequently leads to its activation through self-cleavage driven upon dimerization. 
Active caspase 8 releasing from the DISC complex is capable of activating 
downstream effector caspases, mainly caspase 3 and 7. Consequently, active effector 
caspases proteolytic cleave targeted cellular proteins (PARP-1) and finally ring the 
bell of cell death. In addition to proteolysis target proteins, caspase 3 is able to 
cleave X-linked inhibitor of apoptosis (XIAP), which synergistically strengthen the 
cell death procedure because of establishing a positive feedback loop of 
self-activation [56,57]. 
1.3.1.3 The intrinsic apoptosis pathway 
The intrinsic pathway (or mitochondria-mediated pathway) of apoptosis, as its name 
suggests, requires the involvement of mitochondria. The intrinsic apoptosis can be 
initiated by a wide variety of stress stimuli that include irradiations, DNA damage 
agents, abnormal redox potential, growth factor deprivation, and virus infection 
[58,59]. These various stress stimuli can be sensed by related intra-organellar 
molecules and transduced to mitochondria leading to mitochondrial membrane 
adjustment (Figure 3). The main alterations of mitochondria are characterized with 
changes of mitochondrial outer membrane permeabilization (MOMP) which is 
tightly regulated by Bcl-2 (B-cell lymphoma 2) family proteins especially Bax and 
Bak. Increased MOMP enables release of soluble mitochondrial proteins residing 
between the outer and the inner mitochondrial membrane into the cytosol, including 
cytochrome c, second mitochondria-derived activator of caspases (Smac, also 
known as Diablo, direct IAP-associated binding protein with low pI), apoptosis 
inducing factor (AIF), high temperature requirement A2 (HtrA2) (Figure 3) [60-63]. 
Once released into cytosol, cytochrome c interacts with the adaptor molecule Apaf-1 
(apoptosis protease activating factor) and further triggers the conformational change 
and subsequent oligomerization of Apaf-1. Oligomerized Apaf-1 recruit cytochrome 
c and caspase 9 through the CARD domain resulting in a cart-wheel shaped 
heptameric complex formation, named as apoptosome (Figure 3). Caspase 9 is 
cleaved and activated within the apoptosome. Consequently, active caspase 9 
dissociates from the apoptosome and activate effector caspases (3, 6, and 7) which 
collectively orchestrate the execution of apoptosis [64-66]. In addition to 
cytochrome c, Smac, as natural inhibitor of IAPs through binding to functional 
baculovirus inhibitor repeat (BIR) motif in the cytosol, synergistically promotes 
caspase activation and apoptosis [67,68]. Furthermore, release of HtrA2 from 
mitochondria boosts apoptosis via inhibiting IAPs activities through its four most 
N-terminal amino acids [59]. Moreover, cytosol AIF, releasing from the 
mitochondrial membrane, and finally translocalizes to the cell nucleus where AIF 
promotes complete condensation and fragmentation of chromosomes to initiate 
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apoptosis (Figure 3) [59]. 
Even though the stimuli and most molecules involved in the intrinsic and the 
extrinsic apoptotic pathways are distinct, both pathways final converge at the 
activation of effector caspases. In addition, formation of DISC complex and caspase 
8 activation lead to cleavage of Bid (tBID) and subsequent induction of intrinsic 
mitochondrial amplification loop. In the meanwhile, intrinsic pathway mediated 
release of Smac and HtrA2 increases death receptor-mediated apoptotic pathway 
through synergistically inhibition of XIAP and cIAPs [69-71]. Understanding the 
mechanism of apoptosis and its molecular mechanisms is important as it will help 
develop more effective therapeutic strategies against melanoma through increase 
pro-apoptotic proteins and inhibition of ant-apoptotic molecules. 
 
Figure 3 Molecular mechanisms of the crosstalk between intrinsic and extrinsic 
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signalling pathways in apoptosis. The extrinsic cell death pathway is mediated by 
binding of cytokines (TRAIL, CD95L, TNF) to the respective death receptors 
followed by formation of intracellular protein signalling platforms (DISC or 
TNF-R1 complex I). Activated caspase 8 within the DISC promotes cleavage of Bid 
to a truncated Bid protein (tBid) that links both cell death signalling pathways. The 
intrinsic pathway is further induced via diverse intracellular stress signals that lead 
to release of cytochrome c and formation of the apoptosome that finally promotes 
effector caspases activation. 
1.3.2 Necroptosis  
Necrosis had been regarded as a form of accidental and passive cell death that 
resulted from external injury until recently. Accumulating evidences suggest that a 
cell can initiate demise program through necrosis in a regulated manner under 
extrinsic or intrinsic stimuli. As an alternative form of programed cell death, 
programed necrosis was firstly proposed in 1988 in which TNF was found able to 
induce both apoptosis and necrosis depending on cell types [72]. The existence of 
regulated necrosis was further confirmed with the discovery of serine/threonine 
kinase RIPK1 dependence in CD95L-induced necrosis of Jurkat cells [73]. In 
addition, Chan, et al. in 2003 introduced the term “programmed necrosis or 
necroptosis” to depict the role of TNFR2 in anti-viral response. Another milestone in 
comprehension of the process of regulated necrosis is the revelation of RIPK3 and 
MLKL which are the determinant factors for necroptosis induction [74-77]. 
Necroptotic cells share common morphological characteristics with necrotic cells, 
including increased cell volume, swelling of organelles, and disruption of the plasma 
membrane and release of the intracellular components. Unlike apoptosis, although 
the nuclei of necroptotic cells remain intact instead of breakdown into small bodies, 
the integrity of nuclear membranes is disrupted [78,79]. 
1.3.2.1 Stimuli for Necroptosis 
Tumour necrosis factor (TNF) is most frequently used stimuli for necroptotic cell 
death induction and its mechanism investigation. Whenever caspase 8 is blocked by 
its chemical inhibitors or gene deletion, TNF is able to induce necroptosis in a wide 
variety of cell lines and primary cells. Moreover, antagonists of cellular inhibitor of 
apoptosis proteins (cIAPs) can notably improve the necroptotic cell death [80-82]. In 
addition to TNF, ligation of CD95, TRAILR to their respective ligands can induce 
necroptosis in ways quite similar to TNF [73,83]. Moreover, double-stranded viral 
RNA and lipopolysaccharide (LPS) as ligands for Toll-like receptor 3 and 4 (TLR3/4) 
respectively are able to trigger the necroptosis in macrophages when caspase 8 is 
suppressed by caspase inhibitors [76,84]. Interferons have also been proved to 
possess the ability to induce necroptosis in different cell types [85-87]. In addition to 
biological stimuli, some physical or chemical stress can also promote necroptosis, 
including ionic radiation, photodynamic therapy, calcium overload and anti-cancer 
chemicals as obatoclax, doxorubicin and etoposide [88,89].  
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1.3.2.2 Molecular mechanism of necroptosis 
RIPK1 and RIPK3, as receptor-interacting serine/threonine kinases (RIPKs), are 
critical regulators for necroptosis execution. In respect of molecular structure, 
RIPK1 and RIPK3 share common characteristics: an N-terminal homologous kinase 
domain and a RIP homotypic interaction motif (RHIM). Exclusively in RIPK1, there 
contains a C-terminal death domain that is responsible for RIPK1 interaction with 
TRADD and cIAPs [90,91]. 
The most well studied model of necroptosis is mediated by TNF stimulation. Upon 
ligation with TNF, TNFR1 changes its conformation for trimerization and  further 
recruits TRADD, which in turn interacts with TNF receptor-associated factor 2 
(TRAF2) and TRAF5, RIPK1, and cIAP1/2, termed as TNF complex I [92-95] 
(Figure 4). In complex I, RIPK1 is K63-polyubiquitinated by cIAP1/2 without 
weakening its kinase activity. Poly-ubiquitinated RIPK1 in turn serves as a scaffold 
for the assembly of the transforming growth factor-β-activated kinase-1 
(TAK1)-TAK-1 binding protein 2 and 3 (TAB2/3) complex, which primarily leads 
to the activation of the transcription factor nuclear factor κB (NF-κB) [96,97]. When 
the K63-ubiquitination of RIPK1 is removed or blocked by deubiquitinases 
cylindromatosis (CYLD) or IAP antagonist, complex I dissects from plasma 
membrane and internalized into cytoplasm and form TNF Complex IIa, containing 
TRAF2, RIPK1,TRADD, caspase 8, cFLIP and FADD [92,98]. On the other hand, 
Feoktistova, et al. and Tenev, el al. propose that loss of IAPs is sufficient to promote 
the other complex formation in absence of death ligands, termed as Ripoptosome, 
(Figure 4) which includes RIPK1, caspase10, caspase-8, cFLIP and FADD to induce 
apoptosis [99,100]. Moreover, initiation of TLR signalling enables the interaction of 
RIPK1 and TRIF as a cell death inducing complex. If RIPK3 expresses normally, it 
will be integrated into both complexes though interaction with RIPK1 [73,74,101]. 
In the absence of caspase 8 activity, RIPK1 and RIPK3 keep intact from caspase 8 
mediated cleavage and interact through the RHIM domain to assemble a complex 
with MLKL (mixed lineage kinase-domain like), named as necrosome (Figure 4). In 
necrosome, RIPK1 and RIPK3 utilize kinase activity to phosphorylate each other 
and phosphorylated RIPK3 subsequently initiates the phosphorylation of MLKL. 
MLKL contains a C-terminal pseudokinase domain and an N-terminal four-helix 
bundle (4HB) domain connected by brace domain [102]. Once phosphorylated, the 
pseudo kinase domain performs a conformational change of MLKL resulting in 
exposure of the α-helix of 4HB domain and promotes MLKL oligomerization 
through the brace domain. Oligomerized MLKL is translocalized to plasma 
membrane to disrupt the membrane integrity [103,104]. Several explanations have 
been made to uncover the molecular mechanism for how MLKL oligomer induces 
necroptosis. Cai and his colleagues hold that MLKL oligomerization activates the 
calcium channel protein (Tprm7) and cause calcium influx [105]. Chen, et al. prove 
the role of increased sodium influx in necroptotic cell death [106]. Several studies 
also establish the connection between the oligomerized MLKL and ability to bind 
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negatively charged lipids in the membrane, which facilitates the disintegration of 
plasma membrane [107-109]. 
Due to  their essential role of RIP kinases (RIPKs) in propagation and regulation of 
programmed necrosis, several RIPKs specific inhibitors have been developed, 
including Necrostatin-1, 7-Cl-O-Nec-1, GSK’481, GSK’963 as RIPK1 inhibitors 
[110] and GSK’840, GSK’843, GSK’872 as RIPK3 inhibitors [111]. These 
inhibitors allow us to explore the role of necroptosis in various physiological process 
and diseases, including cell death resistance, inflammation, infection 
ischemia-reperfusion damage, and degenerative diseases and cancer. 
 
Figure 4 The role of molecular signalling platforms for transmission of 
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apoptotic and necroptotic cell death. In absence of cIAPs, membrane-associated 
complex I dissects into cytosol and promotes necrosome formation to induce 
necroptosis. IAP antagonist initiate Ripoptosome assemble and initiated apoptosis 
and necroptosis in absence of caspases activities. 
1.3.3 Regulatory effect of IAPs on programmed cell death 
Melanoma has acquired death resistance during the process of development and 
metastasis. IAP proteins are initially identified as cell death inhibitors in baculovirus 
since they are able to inhibit virus induced apoptosis and allow viral amplification in 
their host cells. With the assistance of bioinformatics, 8 human IAP proteins are 
uncovered, including XIAP, cIAP1, cIAP2, NAIP, Survivin, ML-IAP, Apollon and 
ILP2 [112]. XIAP, cIAP1 and cIAP2, which share structural similarities, are 
well-studied in IAP family. Structurally, there exist an N-terminal three copies of 
~70 amino acids zinc-binding baculovirus IAP repeat (BIR) that is required for 
interaction with caspases and other pro-apoptotic proteins to execute its inhibitory 
effect. In C-terminal there is a carboxyl-terminal RING domain that is characterized 
with E3 ubiquitin protein ligase activity. An ubiquitin associated (UBA) domain 
enables XIAP and cIAPs associate with mono-ubiquitin and poly-ubiquitin chains 
and add ubiquitin chains to target proteins for proteasome-mediated degradation. In 
addition, the cIAPs possess a caspase-recruitment domain (CARD) that is 
responsible for the interaction with adaptor proteins and caspases [113-116]. 
As the nature always keeps balance for adjustment of dominant cellular procedures, 
the natural inhibitor of IAP proteins, Smac/Diablo is found by XIAP 
co-immunoprecipitation [117,118]. Smac interacts with the groove in the BIRs of 
XIAP and cIAP1 via its N-terminal motif to restrain the inhibitory effect of IAPs on 
caspases [119]. This mechanism is applied in designing Smac mimetics, such as 
compound A (Figure 5). Compound A has an amino terminal methyl alanine and 
equivalent binding affinity to XIAP and cIAP1 in the picomolar range. Compound A 
promotes degradation of cIAP1 and cIAP2, and block XIAP activity without 
influencing its expression [120]. In addition to inhibitory effect on IAPs, Compound 
A is able to induce TNF-dependent cell death in some cell lines [120-122]. 
 
Figure 5 Chemical structure of Compound A 
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1.4 Suppression of gene expression and cell death via DNA 
methylation  
DNA methylation as one common form of epigenetic modification was firstly 
proposed in 1980s [123,124]. During mammalian development, DNA methylation is 
involved in the X chromosome inactivation, genomic imprinting and silencing of 
repetitive DNA [125]. Approximately 28 million CpGs are estimated in the human 
genome and 60–80% of them are methylated [126]. When DNA methylation occurs 
abnormally, it results in various human diseases, including cancer, imprinting 
disorders, centromeric instability, immunodeficiency, facial anomalies syndrome, 
Beckwith-Wiedemann syndrome, Prader-Willi syndrome, and Angelman syndrome 
[127]. 
During the process of eukaryotic DNA methylation, methyl groups of 
S-adenosine-methionine (SAM) are added to the cytosine nucleotides of DNA by 
DNA methyltransferases (DNMTs). The modified cytosine residues usually become 
adjoining to a guanine nucleotide and lead to methylation of cytosine residing 
diagonally on opposing DNA strand [128]. Functionally, DNA methylation severs as 
an epigenetic tool to lock genes in the “off” position. In terms of tumours, their 
genome displays global hypo-methylation and promoter hyper-methylation of 
specific genes. Global hypo-methylation frequently at repetitive genomic regions 
results in weakening genomic stability. Hyper-methylation of tumour suppressor 
genes leads to expression suppression [129]. In melanoma, more than 70 abnormal 
hyper-methylated genes have been identified via direct CpG islands methylation 
screen [130]. It has been demonstrated that de novo methylation happens in the early 
phase of carcinogenesis and can be detected in sputum, serum and urine. PTEN, 
SOCS1/2, CDKN2a, RASSF1a and MGMT are reported with aberrant methylation 
detected from peripheral blood of melanoma patients [131-133]. Furthermore, level 
of DNA methylation is considered to be related with melanoma progression [134]. 
These breakthroughs might initiate DNA methylation as a promising marker for 
melanoma detection and prognosis.  
When it comes to the detection of DNA methylation, modifications of DNA samples 
is a prerequisite to differentiate normal cytosine from its methylated counterpart. 
Restriction enzyme digestion in combination with high-performance capillary 
electrophoresis (HPCE) or high-precision liquid chromatography (HPLC) is used to 
estimate the global content of methylation. Methylated DNA immunoprecipitation 
using 5mC-speciﬁc antibodies is applied to enrich the methylated DNA for further 
sequencing. Methylation specific PCR (MSP) and sequencing were developed to 
detect locus-specific DNA methylation after bisulfite converted unmethylated 
cytosine into uracil without change of methylated cytosine. Introduction of 
microarray technologies makes simultaneous analysis of thousands of regions of 
interest accessible. Technological advances in the past two decades have rendered 
comprehensive understanding of DNA methylation. [135]. 
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Since hyper methylation is responsible for silencing of tumour suppressor genes, 
effort has been made to investigate DNA methylation inhibitors as anticancer drugs. 
5-azacytidine (Vidaza) and 5-aza-2’-deoxycytidine (Dacogen) were approved by the 
Food and Drug Administration as epigenetic anticancer agents in 2004 and 2006 
respectively. Solid tumour size reduction was observed upon 5-azaC treatment in 
breast and spleen tumour mouse models [136,137]. Lindner, et al. also reported the 
anti-vascularization as well as the anti-proliferative ability of 5-azadC in melanoma 
[138]. In brief, demethylation reagents are indispensable in comprehension of DNA 
methylation and clinical cancer treatment. 
1.5 Regulation of programmed cell death by NF-κB signalling 
pathway  
1.5.1 NF-κB signalling pathway 
The nuclear factor-κB (NF-κB) transcription factor family has been known as 
principal regulator in responses to a variety of endogenous and exogenous stimuli. 
Mammalian NF-κB is consisted of five homologous proteins including RelA (p65), 
RelB, c-Rel, NF-κB1 p105/p50, and NF-κB2 p100/p52. All NF-κB members share a 
highly conserved Rel homology domain (RHD) at the N-terminus which is 
responsible for homo- or hetero-dimerization, nucleus translocalization, consensus 
DNA sites binding. The RHD domain also enables interaction with inhibitory IκB 
proteins. In addition, RelA, RelB, and c-Rel share a C-terminal transactivation 
domain (TAD) that renders them ability to activate target genes expression 
[139,140]. The activation of NF-κB cascades are characterized into canonical and 
non-canonical pathway in response to various stimuli.  
The canonical pathway is usually initiated by pro-inflammatory and mitogenic 
stimulants such as death ligands, lipopolysaccharides (LPS), interleukin-1 (IL-1). In 
the TNFα-mediated NF-κB activation, RIPK1, cIAP1/2, TRAF2/5, and TRADD are 
recruited to TNFR1 to assemble complex I at the plasma membrane. Within complex 
I, cIAP1/2 add K63-linked ubiquitin chains to RIPK1 serving as a docking site for 
TAK1 and TAB2/3. Different stimuli for NF-κB activation converge at activation of 
a 700-900 kDa trimeric serine-specific IκB kinase (IKK) complex comprised of the 
catalytic subunit IKKα and IKKβ and the regulatory subunit IKKγ (NEMO). The 
activation of IKK complex by phosphorylation results in phosphorylation of IκBα 
allowing its K48-linked ubiquitination and subsequent proteasome degradation 
[141,142]. When cells are in resting state, cytosolic NF-κB p50/p65 dimers are 
binding to inhibitory IκBα leading to mask the nuclear translocation signal. 
Dissociation of IκBα from p50/p65 complex enables entry of this complex into the 
nucleus and its binding to NF-κB DNA sites, which consequently promotes 
transcriptional activation of a wide variety of genes involved in immune and 
inflammatory responses, cell survival and death [143].  
Introduction  15 
 
 
A collection of genetic evidence lead to the discovery of the non-canonical NF-κB 
pathway that is usually triggered by a subset of TNFRS members, including B cell 
activating factor receptor (BAFF-R), CD40, Fn14, receptor activator of NF-κB 
(RANK) and TNF-related weak inducer of apoptosis (TWEAK) receptor [143,144]. 
NIK, known as a constitutive kinase, is usually degraded because of coordinated 
activity of TRAF2/3 and cIAP1/2 [145,146]. The non-canonical NF-κB signalling 
requires NIK stabilization and subsequent activation of IKKα to phosphorylate p100, 
which is in turn ubiquitinated and proteasomal processed into p52. Together with 
RelB, p52 translocates to the nucleus and drives the transcription of a panel of genes. 
1.5.2 Regulatory effect of NF-κB on programmed cell death 
NF-κB, as a family of transcription factors, is involved in cell death regulation by 
initiating related genes expression among other targets.  
Initially, NF-κB activation is considered as negative regulatory signalling for cell 
death. It has been demonstrated by several studies that NF-κB activation is able to 
inhibit cell death induced by distinctive stimuli in a wide variety of cells. NF-κB 
activation exerts its inhibitory effect on cell death by inducing the transcription of 
anti-apoptotic genes or genes that negatively regulate cell death. NF-κB activation 
promotes expression of pro-survival Bcl-2 members, including A1, Bcl-xL, Bcl-2 
[143]. In addition, NF-κB blocks cell death through repression of pro-apoptosis 
proteins, such as Bax and Bim in some cells. IAPs, cFLIP, TRAF1 and TRAF2, as 
inhibitory components for both apoptosis and necroptosis, are upregulated when 
NF-κB activates. In addition, NF-κB activation also increases expression of 
ubiquitin-edit enzymes including A20 and CYLD. By expression of direct cell death 
inhibitors or indirect cell death regulators, NF-κB protects cells from death 
[139,147,148]. Moreover, a variety of studies have proved that activation of nuclear 
factor-kappa B (NF-κB) is involved in the tumour progression and metastasis of 
melanoma [148-151].  
Although NF-κB mainly exhibits inhibitory effect on cell death in most cases, it can 
behave in an anti-survival manner in some instances. Cytokines and chemokines 
production including interleukins, interferons, TNF, TRAIL and Fas ligand which are 
tightly related with immune response are increase upon NF-κB activation [152]. 
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2. Materials and Methods 
2.1 Chemicals and Buffers 
Table 1 Chemicals for buffer solution 
Chemicals Company Catalog No. 
4-(2-Aminoethyl)-benzene sulfonyl 
fluoride (AEBSF) hydrochloride 
AppliChem A1421 
Ampicillin sodium salt  Roth K029.1 
Aprotinin Roth A162.3 
Bis-Tris  AppliChem A1025,0500 
Bovine serum albumin (BSA)  Santa Cruz  sc 2323A 
Bromophenol blue Sigma-Aldrich B8026 
Calcium chloride dihydrate (CaCl2·2H2O)  Sigma-Aldrich  C3306 
cOmplete™ protease inhibitor cocktail 
tablets 
Roche 11836145001 
Crystal violet  AppliChem A0691.0250 
di-Sodium hydrogen phosphate dihydrate  Roth 4984.1 
Dithiothreitol (DTT) AppliChem A2948.0025 
Ethanol denatured (≥99.8%) Roth  K928.4 
70% Ethanol denatured Roth  T913.2 
FACS shutdown solution  BD Biosciences 334224 
FACS flow sheath fluid  BD Biosciences 342003 
Glycerin ROTIPURAN®  Roth  3783.2 
HEPES Sigma-Aldrich H3375-1KG 
Hoechst 3342 Polysciences 09460-100 
Methanol analaR NORMAPUR®  VWR 20847.360 
MOPS for buffer solutions  AppliChem A1076,1000 
Leupeptin Sigma-Aldrich L2884 
Potassium dihydrogen phosphate 
(KH2PO4)  
Roth 3904.1 
Potassium chloride (KCl)  Roth 6781.3 
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Propidium iodide (PI)  Sigma-Aldrich 81845-100MG 
SDS Pellets  Roth CN30.3 
Skim milk powder  Sigma-Aldrich 70166-500G 
Sodium chloride (NaCl)  Roth 3957.2 
Sodium citrate dihydrate 
(C6H5Na3O7·2H2O) 
Sigma-Aldrich 
W302600 
Sodium hydroxide (NaOH) solution (5M)  Roth KK71.1 
Sodium orthovanadate (Na3VO4)  Sigma-Aldrich S6508 
SYTOX® Green nucleic acid stain Life technologies S7020 
Tris ultrapure AppliChem A1086,1000 
Triton X-100  AppliChem A1388,0500 
Tween 20  Roth 9127.3 
β-Glycerophosphate disodium salt hydrate  Sigma-Aldrich  G9422-10G 
β-Mercaptoethanol  Merck Millipore 805740 
LB-Agar (Lennox) Roth X965.2 
LB-Medium (Lennox) Roth X964.2 
Table 2 Buffer composition 
Buffer Ingredients 
10X Annexin V binding Buffer 0.1 M HEPES (pH 7.4), 1.4 M NaCl, 25 mM 
CaCl2 solution 
Blocking Buffer 5% (w/v) non-fat dry milk, 3%(w/v) BSA in 1X 
T-PBS 
Crystal violet staining solution 0.5% (w/v) crystal violet powder, 20% (v/v) 
methanol 
2X HBS Buffer (pH7.05) 280 mM NaCl, 50 mM HEPES, 1.5 mM 
Na2HPO4 
5X Laemmli Buffer 60 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% 
(v/v) Glycerol, 5% (v/v) β-Mercaptoethanol, 
0.01% (w/v) Bromophenol blue 
Lysis Buffer 30 mM Tris-HCl (pH 7.5), 120 mM NaCl, 10% 
(v/v) Glycerol, 1% (v/v) Triton X-100, 2 tablets 
Complete protease Inhibitor cocktail per 100 ml 
1X PBS Buffer (pH 7.4) 2.7 mM KCl, 1.5 mM KH2PO4, 137 mM NaCl, 
8 mM Na2HPO4 
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1X PBS-T 1X PBS, 0.1%(v/v) Tween 
MOPS Buffer (pH 7.7) 50 mM MOPS, 50 mM Tris-base, 0.1% (w/v) 
SDS, 1 mM EDTA 
Triton lysis buffer for 
phosphoprotein assays 
20 mM Tris (pH 7.4), 1% (v/v) Triton X-100, 
10% (v/v) glycerol, 137 mM NaCl, 2 mM 
EDTA, 50 mM β-Glycerophosphate disodium 
salt hydrate, 1mM sodium orthovanadate; 
Before use, added, 1 mM ABSF, 5 μg/ml 
aprotinin, 5 μg/ml Leupeptin hemisulfate salt,  
5 mM benzamidine. 
Table 3 Reagents and Kits 
Reagents and Kits company Catalog No. 
Agarose (low melt) Roth 6351.5 
Blood & Cell culture DNA Mini kit QIAGEN 13323 
dNTPs mix (10 mM) Thermo Scientific R0193 
GeneRuler 1 kb DNA ladder  Thermo Scientific SM0312 
GeneRuler 100 bp DNA ladder  Thermo Scientific SM0242 
iBlot 2 Transfer stacks Life technologies IB24001 
KAPA SYBR FAST Universal  Peqlab 07-KK4600-03 
Luminata Forte Western HRP substrate  Merck Millipore WBLUF0500 
Nancy-520  Sigma-Aldrich 01494 
NuPAGE Novex 4-12 % Bis-Tris Protein 
Gels 
Invitrogen NP0329BOX 
PerCP/Cy5.5 Annexin V Biolegend 640936 
PageRuler prestained protein ladder  Life technologies 26617 
Pierce ECL Western Blotting substrate  Thermo Scientific 32106 
Protein Assay Reagent A  Bio-Rad 5000113 
Protein Assay Reagent B  Bio-Rad 5000114 
Protein Assay Reagent S  Bio-Rad 5000115 
Protein G agarose beads Roche 05015952001 
Restore Western Blot stripping buffer  Thermo Scientific 21063 
RNaseOUT recombinant ribonuclease 
inhibitor 
Invitrogen 10777-019 
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SuperScript II reverse transcriptase  Invitrogen 18064-071 
E.Z.N.A. FastFilter plasmid Maxi kit  OMEGA D6924-04 
Microlance™ needles (No.27G) Becton Dickinson BD300645 
EZ DNA METHYLATION™ kit ZYMO Research D5001 
2.2 Methods  
2.2.1 Cell culture 
Human melanoma cell lines: A375, PM-WK, RPM-MC, RPM-EP, SK-MEL28, 
PREYER, MeWo, IGR, MM-RU, MM-AN, MM-LH, WM1346; 
Spontaneously transformed aneuploid immortal keratinocyte cell line: HaCaT; 
Human Primary melanocytes: #19, #20; 
Human Primary nevus cells: #5, #8; 
Murine melanoma cell lines: Ret1, Ret2, HcMel3, HcMel12, HcMel31; 
Murine immortalized keratinocytes 
Table 4 Cell culture medium and related reagents 
Medium and Reagents Company Catalog No 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich H7904 
Dulbecco’s Modified Eagle Medium 
(DMEM), GlutaMax, high Glucose  
Gibco 61965-059 
Dulbecco’s phosphate-buffered salines 
(DPBS) 
Gibco 14040-174 
Ethylenediaminetetraacetic acid (EDTA) Merck Millipore L2113 
Fetal bovine serum (FBS)  Gibco 10270-106 
HEPES solution (1 M, pH 7.0-7.6) Sigma-Aldrich H0887 
Hygromycin B A&E Scientific P21-014 
Lipofectamine® 2000 Transfection 
Reagent 
Invitrogen 11668-019 
Melanocyte Growth Medium 
(Ready-to-use) 
Promoc  Cell C-24010 
PCT Epidermal Keratinocyte Medium CELLnTEC CnT-07 
Opti-MEM®I Reduced Serum Medium Gibco 31985-047 
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Polybrene (Hexadimethrine bromide) Sigma-Aldrich H9268-5G 
Puromycin dihydrochloride Gibco A11138-03 
RPMI1640 medium Gibco 21875-091 
Sodium pyruvate Gibco 11360-088 
Trypsin (2.5%, 10X)   Invitrogen 15090-046 
Zeocin™ selection reagent Gibco R250-01 
(Z)-4-Hydroxytamoxifen (4-HT) Sigma-Aldrich H7904 
Human melanoma cells and transformed keratinocytes were cultured in DMEM 
medium containing 10% FBS, 1% HEPES, 1% sodium pyruvate, and 1% MEM 
amino acids at 37°C in 5% CO2. Human primary melanocytes and nevus cells were 
cultured in melanocytes growth medium with its supplement medium at 37°C in 5% 
CO2. Murine Melanoma cell lines were cultured in RPMI 1640 medium containing 
10% FBS, 1% HEPES, 1% sodium pyruvate, and 1% MEM amino acids at 37°C in 5% 
CO2. Murine immortalized keratinocytes were cultured in PCT epidermal 
keratinocyte medium containing respective supplements and 10% chelex treated 
FBS at 37°C in 5% CO2. 
Cells were trypsinized for further subculture or experimental purposes. Cells were 
washed by DPBS and detached using 2.5% trypsin for 5 minutes. Medium 
containing 10% FBS was used to neutralize trypsin and make homogenous cell 
suspension. To collect cell pellets, cell suspension was spun down at 400 x g for 5 
minutes at room temperature. Following discarding supernatant, cell pellets were 
resuspended with fresh medium for culturing or experimental use.  
2.2.2 Cell death assay  
Cells were pretreated or treated with following reagents alone or in combinations as 
indicated. Then cell death was analysed with following methods: 
Table 5 Cytokines and inhibitors 
Item Source Catalog No. 
CD95L-Fc M. Feoktistova [153]  
z-Val-Ala-DL-Asp-fluoromethylketone 
(zVAD-fmk) 
Bachem N15100025 
5-Aza-2’-deoxytidine Sigma-Aldirich A3656-10MG 
Necrostatin-1 Sigma-Aldrich N9037-25MG 
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Necrosulfonamide (NSA) Merck Millipore 480073-25MG 
Compound A (IAP antagonist) Tetralogics  
GSK’481 Glaxo Smith Kline  
7-Cl-O-Nec-1 Glaxo Smith Kline  
GSK’840 Glaxo Smith Kline  
GSK’872 Glaxo Smith Kline  
Dabrafenib Selleckchem S2807 
Vemurafenib Selleckchem S1267 
2.2.2.1 Crystal Violet staining 
Crystal violet solution was used to stain attached, living cells following stimulation. 
1x104 cells were seeded into 96-well plates one day before stimulation. Then cells 
were treated with the indicated concentrations of stimulating agents in absence or 
presence of inhibitors in 96-well plates overnight. Before staining, plates were 
gently washed with PBS twice. Subsequently, 50 μl of crystal violet staining 
solution (Table 2) were added per well and the plates were stained on a shaker for 
30 minutes at room temperature. After incubation, plates were washed with water to 
remove the non-intercalated crystal violet. Plates were air dried, and then 200 μl 
methanol (Table 2) was added per well followed by 30min incubation at RT to solve 
the incorporated dye. The optical density (OD) of the samples was measured with 
Victor3™ Multilabel Reader (Perkin Elmer). The OD of control (cells treated with 
diluents) was normalized to 100% and compared with stimulated cells. For 
statistical analysis, the Standard Error of Mean (S.E.M.) was determined for at least 
of medium of three independent experiments of each cell line and stimulatory 
condition. 
2.2.2.2 Annexin V/PI staining 
To detect the externalization of phosphatidylserine to the outer plasma membrane 
and change of permeability of nuclear membrane during cell death, Annexin V/PI 
dual staining was used. Firstly, 2x105 cells were seeded into 6-well plate per well. 
Cells stimulated with indicated reagents as described. After overnight stimulation, 
cells were collected by trypsinization, washed twice in 1X PBS (Table 2), and 
resuspended in 100 μl Annexin V binding buffer (Table 2) at a cellular concentration 
of 1x 106 cells/ml. 5 μl Annexin V-Cy5 and 5 μl PI (Table 2) were added to cell 
suspension and incubated for 15 min at RT in the dark after mixing. 400 μl Annexin 
binding buffer was added to the samples before they were analysed via flow 
cytometry and the FACSCanto™ II (BD Biosciences). 
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2.2.2.3 Hoechst 3342 and SYTOX
®
 Green dual staining 
To detect the nuclear morphology and the integrity of the plasma membrane, 5x104 
cells of the respective cell lines were seeded per well into a 12-well plate. Next day, 
cells were stimulated as indicated concentrations overnight. 8 hours later, cells were 
stained with Hoechst 33342 (5 μg/ml) and SYTOX® Green (5 pM) (Table 1) for 
15min at 37°C and then visualized with phase contrast Axio Observer Z1 (Zeiss) 
fluorescence microscopy. 
2.2.3 Plasmid transformation and isolation 
To expand the amount of plasmids of interest (Table 6), chemically competent 
TOP10 E.Coli cells were incubated with plasmids for 30 minutes. Then the mixture 
was heat shocked at 42°C for 45 seconds and put back in ice again for 3 minutes. 
Followed by adding 500 μl SOC medium without antibiotic, competent cells/DNA 
mixture was further cultured in shaking incubator at 37°C for 45 minutes. 
Transformation product was plated on pre-warmed LB agar plates containing 
appropriate antibiotics at 37°C overnight. After successful transformation, single 
colony were picked and further cultured in Erlenmeyer flask containing 200 ml LB 
medium (Table 1) with antibiotics 37°C overnight. Plasmid was isolated and 
purified with the E.Z.N.A Fastfilter Plasmid Maxi Kit (Omega) according to the 
manual. The concentration of plasmid was measured using a NanoDrop 2000™ 
(ThermoFisher SCIENTIFIC) spectrophotometer. 
Table 6  Plasmids 
Vector Antibiotic Inserts 
pCFG5-IEGZ Ampicillin, Zeocin RIPK3; 
RIPK3KD 
pFGEV16-Super-PGKHygro Ampicillin, Hygromycin B  
pF 5 × UAS W SV40 Puro (L27) Ampicillin, Puromycin  IKK2EE; 
IKK2KD 
2.2.4 Ca-phosphate mediated transfection of lentiviral or retroviral 
DNA and virus production 
HEK293T cells or ΦNX-AMPHO cells (amphotrophic producer cell line) were 
grown into 10 cm plates with 3x 106 cells per plate. Then the medium was freshened 
with 6 ml of respective medium containing 25 μM Chloroquine per plate at 37°C in 5% 
CO2. To generate Ca-Phosphate-DNA complex precipitates, 20 μg retroviral DNA or 
10 μg lentiviral with 3 μg pMD2.G, 7.5 μg pSPax2, and 3 μg pcDNA3.1/p35 were 
mixed up with CaCl2 respectively to 500 μl as final volume per plate.  The formed 
complex mix was dropwise added into the 500 μl 2X HBS buffer (Table 2) with air 
blowing. Followed by 30 minutes incubation at RT, the mix was dropwise added to 
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the cells and incubated over night at 37°C in 5% CO2 atmosphere. The supernatant 
containing lentiviral or retroviral particle of 48 hour and 72 hour post-transfection 
were collected, filtered (0.45 μm), shock frozen by liquid nitrogen and stored at 
-80°C for future use. All steps described were completed according to the safety 
class 2 requirements. 
2.2.5 Retroviral and lentiviral transduction 
The supernatants containing viral particles (from method 2.2.4) and 5 μg/ml 
polybrene (Table 4) were added to cells of interest. Target cells were 
spin-transfected at 2300 rpm for 90 minutes at 30°C. Next day cells were washed 
and freshened with new medium. Stable cell lines were selected with respective 
antibiotics. For the inducible protein expression the transduced cells were stimulated 
with 100 nM 4-HT (4-Hydroxytamoxifen, Table 4) for 24h. Western blot analyses 
were performed to confirm ectopical expression of the respective molecules. 
2.2.6 CD95 Receptor staining 
2x 105 cells of interest were seeded in 6-well plates and incubate for 24 hours. Cell 
pellets were harvested by trypsinisation. Then cells pellets were washed once with 
PBS and resuspended with 100 μl FACS buffer followed by addition of anti-CD95 
primary antibody (Table 7) to 10 μg/ml for 1 h at 4 °C. The cells were washed with 
PBS and resuspended with 100 μl FACS buffer containing 1 μl of the secondary 
antibodies (anti-mouse IgG1-Biotin). Samples were incubated for 30 min at 4 °C and 
again washed with PBS. Then, 100 μl FACS buffer containing 1μl of the tertiary 
staining reagent (PE-Cy5 Streptavidin) was added to the cells and the samples were 
incubated for 30 min at 4 °C. Cells were again washed with PBS, dissolved in 500 μl 
FACS buffer, and measurement was performed via flow cytometry and the FACS 
Canto II as described above. 
2.2.7 Western blot analysis  
2.2.7.1 Cell lysate preparation 
For generation of total cell lysates, cells were collected by trypsinisation, washed 
twice with ice-cold 1X PBS and lysed for 1 hour on ice by the addition of cell lysis 
buffer (Table 2). Cellular debris was removed by centrifugation at 20,000 x g for 30 
min at 4℃. The total amounts of isolated cell proteins were quantified by Bradford 
assay as described below. 5 μg of total cellular proteins was supplemented with 5X 
Laemmli sample buffer (Table 2) and denatured at 95°C for 5-10 min. 
For analysis of phosphorylated proteins, the respective cells were starved in serum 
free medium for 6 h to get rid of the basal phosphorylation activated by addition of 
FBS. Then the cells were scraped from the plate and resuspended in phosphor-lysis 
buffer containing phosphatase inhibitors (Table 2). To quickly disrupt the cell 
membranes the lysates were homogenized by pushing three times through a syringe 
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with 0.4 mm Microlance needle, followed by 20,000 x g centrifugation for 30min. 
2.2.7.2 Protein concentration determination 
Protein concentration was measured using the DC™ Protein Assay (BioRad) 
according to instructions. In brief, 5 μl protein lysate was added to a 96-well plate. 
Then 25 μl reagents S’ (A:S 50:1) were added to each cell followed by addition of 
200 μl reagents B. The plate was mixed at room temperature and measured at 750 nm 
using VICTOR3™ 1420 Multilable Reader (Perkin Elmer). 
2.2.7.3 Western Blot analysis 
Total lysates were loaded on NuPAGE 4-12% BisTris gradient gels (Table 2) and 
proteins were separate using MOPS running buffer (Table 2). PageRuler prestained 
protein ladder (Table 3) was loaded on the same gel as a standard for protein 
separation and molecular weight. 
Proteins were transferred to PVDF (polyvinylidene difluoride) membrane using 
iBlot2 Transfer Stacks (Table 2) according to the manual. Membranes were blocked 
for 1 h in blocking buffer (Table 2) and incubated with primary antibodies (Table 7) 
overnight. Subsequently, membranes were washed 4 times in 1X T-PBS for 10min, 
and then incubated with corresponding HRP-conjugated isotype-specific secondary 
antibody (Table 7) diluted in 5% non-fat milk for 1 hour at RT. After 4 times washing 
with 1X T-PBS, the blots were visualized with Pierce ECL Western Blot substrate 
(Table 3) or Luminata Forte Western blot HRP (Table 3) and films (AGFA Curix HT 
and GE Hyperfilms). Films were developed with Curix 60 (AGFA) developing 
machine. 
Table 7 Primary and secondary antibodies 
Antibody Isotype Source Catalog No. 
A20 (TNFAIP3) Mouse IgG1 Imgenex IMG-161 
β-Actin Mouse IgG2a Sigma Aldrich A2228-100UL 
Caspase-8 Mouse IgG2b Provided by P.H. Krammer 
Caspase-8 Goat IgG Santa Cruz sc-6136 
CD95 Mouse IgG1 Provided by P.H. Krammer 
cIAP1 Rat  provided by J. Silke 
cIAP2 Rat provided by J. Silke 
cFLIP(NF6) Mouse IgG1 Enzo Life Science ALX-804-961-0100 
ERK2 (C-14) Rabbit Santa Cruz sc-14 
phosph-ERK1/2 Mouse IgG Santa Cruz sc-16982 
FADD Mouse IgG1 BD Biosciences F36620 
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2.2.8 Caspase-8 Co-immunoprecipitation 
For the precipitation of caspase 8-bound proteins, 2x 107 cells were seeded and 
incubated overnight. Cells were washed once with medium at 37°C and 
pre-incubated with zVAD-fmk (10 μM) for 1h and followed by addition of IAP 
antagonist (100 nM) at 37°C. After 4 hours stimulation, cell pellets were harvested 
by trypsinisation, centrifugation and washing. Subsequently cells were lysed in 1ml 
lysis buffer by gently shaking with tube rotator at 4°C. 1hour later, the lysates were 
centrifuged two times at 20,000 x g for 30min to discard cellular debris. A minor 
fraction of these clear lysates were used as control for the input of the respective 
proteins (total lysates) and prepared as indicated in method 2.2.7.1. Meanwhile, a 
total amount of 3mg protein was used and mixed well with 1 μg caspase 8 antibody 
(Table 7). The caspase 8 containing complexes were precipitated from the lysates by 
co-incubation with 60 μl protein G-beads (Roche) for 16-24h on a tube rotator at 4°C. 
Beads were washed 4 times with cold lysis buffer before the protein complexes were 
eluted from dried beads by addition of standard reducing Laemmli buffer and boiling 
IκBα Rabbit IgG Santa Cruz sc-371 
Phospho-IκBα Rabbit IgG Cell Signaling 9246 
IKKα/β Rabbit IgG Santa Cruz sc-7607 
MLKL Rat Provided by James Murphy 
Phospho-MLKL(S158) Rabbit IgG Abcam ab187091 
RIPK1 Mouse IgG2a BD Biosciences R41220 
Phospho-RIPK1(S166) Rabbit IgG Provided by P.Gough 
RIPK3 Rabbit IgG Imgenex IMG-5846A 
NF-κB2 p100/p52 Rabbit IgG Cell Signaling 4882S 
XIAP Mouse IgG1 BD Biosciences H62120 
Secondary Antibodies 
Mouse IgG1 Goat/HRP SouthernBiotech 1070-05 
Mouse IgG2a Goat/HRP SouthernBiotech 1080-05 
Mouse IgG2b Goat/HRP SouthernBiotech 1090-05 
Mouse IgG Goat/HRP SouthernBiotech 1030-05 
Mouse IgG1-Biotin Goat SouthernBiotech  1030-08 
rabbit Goat/HRP SouthernBiotech 4030-05 
Rat Goat/HRP SouthernBiotech 3030-05 
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at 95°C for 10 min. Finally the total lysate and IP samples were analysed by western 
blot as indicated in method 2.2.7.3. 
2.2.9 RNA isolation and reverse transcription 
RNeasy Mini Kit (Table 3) was used for isolation and purification of total RNA from 
adherent cell lines according to the manual. Firstly, the cell pellets were disrupted 
and homogenized with 1% β-mercaptoethanol containing RLT buffer and 
QIAshredder (Qiagen). Then the samples were washed and purified by using spin 
column. Last, total RNA was eluted from the columns by RNase free water. RNA 
quality and quantity were determined using the NanoDrop 2000™ (ThermoFisher 
SCIENTIFIC) spectrophotometer. 
For the reverse transcription reaction, 1-2 μg RNA of each sample was used. 1 μl 
dNTP (10 mM), 1 μl random nonamers (100 μM), 0.2 μl oligodT primer (100 μM) 
and RNase free water were mixed with RNA to a final volume of 12 μl and incubated 
in a thermocycler for 5 min at 65 °C. 
Afterwards, 4 μl 5X First Buffer, 2 μl DTT (0.1 M), 0.5 μl RNaseOUT and 0.5 μl 
Superscript® II reverse transcriptase (Table 3) were added into the reaction tubes. 
The samples were further incubated in a thermocycler for 2 min at 42 °C, 12 min at 
25 °C, 50 min at 42 °C, and finally 15 min at 70 °C. cDNA samples were collected 
from the reaction tubes and diluted to a final concentration of 10 ng/μl for qPCR. 
2.2.10 Quantitative real time polymerase chain reaction (qPCR) 
Primers listed in Table 8were designed with Primer3 software. qPCR experiments 
were performed in triplicates using KAPA SYBR® FAST Master Mix (2X) Universal 
as following Table 9 
Table 8 qPCR primers 
Primer Forward Revers 
RIPK3 CAAGATCGTAAACTCGAAGG  CCTGGTATGACAACGAATTT 
TNF GGCAGTCAGATCATCTTCTC TGGTTATCTCTCAGCTCCAC 
GAPDH GTGAGGGTCTCTCTCTTCCT CCGTTCTCCATGAATTTAGT 
Table 9 Reaction components for PCR 
Component Volume(μl)/ rxn Final Conc. 
PCR grade water Up to 20 μl N/A 
2X KAPA SYBR® FAST qPCR Master Mix 10 1X 
Forward Primer (10μM) 0.4 200nM 
Reverse Primer (10μM) 0.4 200nM 
Template cDNA 100ng 5ng/μl 
50X ROX Low 0.4 1X 
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Table 10 Thermal cycling profile for qPCR 
Temperature time cycles 
95 °C 15 min 1 
95 °C  
60 °C  
72 °C  
30 s 
30 s 
30 s 
40 
40 
40 
95 °C  
60 °C  
95 °C  
60 s 
30 s 
30 s 
1 
1 
1 
Melting curve analysis was used to confirm the specific amplification of a single 
product of the expected size for gene of interest. Furthermore, all primers used for 
qPCR studies have been tested before by cDNA dilution curves to show efficiency 
within 80-110 %. In addition, all samples were tested to have a low variance in the 
housekeeping gene (GAPDH) expression (< 2 cycles). Serial dilutions of cDNA (1, 
1/5, and 1/25) were amplified for the construction of a standard curve and used for the 
estimation of the pPCR efficiency using MxPro software (Agilent Technologies). The 
relative quantification was calculated after dividing the standard curve value of the 
respective genes by that of the housekeeping gene (GAPDH) for each individual 
sample using Excel.  
2.2.11 Genomic DNA isolation  
Blood & Cell Culture DNA Mini Kit (Table 3) was used for isolation and 
purification of genomic DNA from adherent cell lines according to the manual. 
Briefly, cells were harvested using trypsin and washed with cold PBS. Then cells 
were resuspended with cold PBS to a final concentration of 107cells/ml and lysed 
with lysis buffer. Protein was removed by addition of Protease K for incubation 45 
minutes. DNA was purified and collected with Genomic-tip (Qiagen). The quality 
and quantity of DNA were determined using NanoDrop 2000™ (ThermoFisher 
SCIENTIFIC) spectrophotometer. 
2.2.12 Bisulfite conversion of DNA and Methylation specific PCR 
(MSP)  
Methylation specific PCR (MSP) was used to determine the locus specific 
methylation of genes of interest. Firstly, purified genomic DNA was treated with 
bisulfite sodium (EZ DNA Methylation™ Kit) to convert unmethylated cytosine into 
uracil without alteration of methylated ones. Bisulfite modified DNA was collected 
with zymo-spin™ columns used for further PCR analysis. Once converted, the 
methylation profile of the DNA can be determined by PCR amplification with 
specific primers. In this study, two pairs of primers recognize the original sequence 
and the rest two are specific to the modified sequences with predictive methylation 
locus (Table 11) [154]. M indicates primers recognising methylated sequences and 
28  Materials & Methods 
U indicates primers recognising unmethylated sequences. The MSP reaction was 
performed under following conditions: 
Table 11 RIPK3 primers for MSP 
Primer Forward Revers 
RIPK3 M1 TAATTCGGAAAAAGGGTAATAATTC ATAAATATCGAAAACTACGATCGAC 
RIPK3 U1 AATTTGGAAAAAGGGTAATAATTTG ATAAATATCAAAAACTACAATCAAC 
RIPK3 M2 AGGTTATGGTAAGTTTGGATAACGA CAACAAACGACAAAAAAACGAC 
RIPK3 U2 AGGTTATGGTAAGTTTGGATAATGA CTTTCAACAAACAACAAAAAAACAA 
Table 12 Reaction components for PCR 
Component Volume(μl)/ rxn Final Conc. 
DreamTaq DNA polymerase 1 1X 
5X DreamTaq Green buffer 5 1X 
Forward Primer (10μM) 0.5 200 nM 
Reverse Primer (10μM) 0.5 200 nM 
Template cDNA 40 ng 1.6 ng/μl 
PCR grade water  Up to 25 μl N/A N/A 
Table 13 Thermal cycling profile for MSP 
Step Temperature time cycles 
1. Initial denaturation 
denaturation 
95 °C 
95 °C  
10 min 
30 s 
1 
45 
2. Annealing 56 °C  30 s 45 
3. Elongation 72 °C  
72 °C 
30 s 
10 min 
45 
1 
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3. Aim of the thesis 
Malignant melanoma is the most dangerous form of skin cancers due to its 
aggressiveness and resistance to existing therapies. Genetic and epigenetic 
abnormalities of specific genes and inadequacy of the intracellular signal 
transduction resulted in aggressiveness of melanoma cells. Development of 
melanoma is highlighted by activation of molecular mechanisms that directly 
influence regulation of cell death, cell proliferation and cell survival processes. 
The resistance to cell death stimuli is one of the hallmarks of tumour cells to escape 
host specific elimination. Melanoma cells are easily gaining resistance to either 
extrinsic or intrinsic cell death stimuli during its development. Inhibitor of apoptosis 
proteins (IAPs) are such negative regulators of cell death. Therefore overcoming cell 
resistance by antagonising or downregulation of IAPs has been advocated as a 
effective strategy for tumour therapy. In view of these facts of cell death and 
melanoma, the project will be started with the investigation of the role of IAPs in cell 
death resistance in melanoma. To identify the regulatory proteins in melanoma, 
CD95 ligand (CD95L), as a death ligand, will be firstly used to study the basal cell 
sensitivity and forms of cell death in melanoma. Apoptosis and necroptosis, as main 
forms of cell death, will be investigated in melanoma. The possible cell death forms 
will be characterized by biochemical and morphological analysis. To conclude the 
role of IAPs in melanoma cell death, the expression profile of IAPs in melanoma will 
be screened and its function will be confirmed by usage of its antagonist. Application 
of specific inhibitors will further support the regulatory effect of proteins on 
melanoma cell death. 
In addition to cell death resistance, acquired gene mutations and epigenetic 
modifications can also be responsible for cell death resistance of melanoma cells. To 
identify if such epigenetic modifications influence the regulation of programmed cell 
death, we will check the methylation status of DNA of genes involved in apoptotic 
and necroptotic cell death responses in melanomas. Here we will perform 
overexpression to reconstitute expression of methylated genes to confirm their 
function in programmed cell death. In addition, knockdown or chemical inhibitors of 
the specific molecules will be performed for further verification. 
Since NF-κB is involved in transcriptional regulation of proteins that control cell 
proliferation, cell survival and cell death resistance, the regulatory impact of NF-κB 
activation in melanoma cell death will be evaluated. To investigate the role of the 
NF-κB signalling for cell death responses in melanoma, we will firstly identify 
anti-apoptotic proteins, of which expression and modifications are influenced by 
NF-κB, by artificial generation of melanomas with constitutive active or inactive 
IKK2. Subsequently, the effect of NF-κB-mediated protein expression on cell 
sensitivity will be screened and analysed in melanomas.
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4. Results 
4.1 Identification of regulatory proteins for programmed cell 
death in melanomas 
Escape from intrinsic self-check mechanism for programed cell death is one 
hallmark of tumours [155]. Primary or acquired cell resistance render melanoma 
cells ability for survival and metastasis. Previous studies have confirmed the 
negative role of IAPs in cell death regulation [97,117,153]. Therefore, it was 
proposed that IAPs could be negative regulators for cell death in melanoma. In 
addition, RIPK1-RIPK3-MLKL platform mediates programed necrosis under 
specific stimulation conditions [79,105,156]. Accordingly, the regulation of 
necroptosis will be studied in melanoma. 
4.1.1 Loss of IAPs sensitizes human melanoma cells to 
CD95L-induced cell death 
Melanoma acquires death resistance during development and metastasis. IAP 
proteins are initially identified as cell death inhibitors through weakening caspases 
activity and other proteins required for cell death execution. Therefore IAPs play as 
negative regulators of cell death and related with cell death resistance. To identify the 
effect of IAPs on regulation of CD95L-induced cell death, endogenous expression 
levels of cIAP1, cIAP2 and XIAP of melanoma cell lines from different tumour 
stages were firstly compared with primary melanocytes, primary nevus cells, and 
spontaneously transformed aneuploid immortal keratinocyte cell line (HaCaT) 
(Figure 6A). cIAP1 was expressed in all cell lines but with relatively low level in 
PREYER, MeWo and MM-LH cells. Moreover, one additional band with higher 
molecular weight of cIAP1 was detected in primary melanocytes, nevus cells (#5, #8), 
as well as in SK-MEL 28 and MM-AH melanoma cells, suggesting that in these cells 
cIAP1 might be modified post translation. On the contrary, cIAP2 was only 
detectable in A375, RPM-EP and HaCaT cells but not in other cell lines. XIAP, 
which was absent in HaCaT cells, was expressed more in human melanoma than 
melanocytes or nevus cells (Figure 6B). In summary, cIAP1 and XIAP both were 
expressed normally in cultured human melanomas and primary cells, which 
suggested the potential relationship between IAPs expression and cell death 
resistance. 
Furthermore, to further confirm the relevance of IAPs expression and negative 
regulatory effect on melanoma cell death, the IAP antagonist (Compound A, Figure 
5) was used to downregulate the intrinsic cIAPs levels and to suppress XIAP activity. 
Compound A was sufficient to downregulate both endogenous expression of cIAP1 
and cIAP2 with low concentrations in 1 hour. Moreover, Compound A showed 
relatively significant inhibitory effect on cIAP1 expression compared with cIAP2. 
Meanwhile, Compound A blocked XIAP activity without altering its protein 
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expression (Figure 6B). Our results indicated that whenever expression or activity of 
IAPs was blocked by Compound A, melanoma cells exhibited increased cell 
sensitivity to CD95L in vitro (Figure 6A). To investigate if this observed decrease of 
cell viability was caspase-dependent apoptosis or PRIPK1-dependent necroptosis, 
the effect of pan-caspase inhibitor zVAD-fmk and the RIPK1 inhibitor 
Necrostatin-1 on cell death was analysed by Annexin V/Propidium iodide (PI) dual 
staining (Figure 6D). In our study, caspase inhibitor but not RIPK1 inhibitor 
protected melanoma cells from CD95L/IAP antagonist-induced cell death, which 
indicated that caspase-dependent apoptosis was the dominant cell death form in 
melanoma cells. Our results confirmed that IAPs, especially cIAP1 and XIAP were 
negative regulatory elements for CD95L-mediated cell death in melanoma cell lines. 
In addition, CD95L dominantly induced caspase-dependent apoptosis but not 
unmasked RIPK1 dependent necroptotic cell death in melanoma in vitro indicating 
that the molecules involved in necroptosis could be absent in melanomas. 
 
Figure 6 Loss of IAPs sensitizes melanoma cell lines to CD95L-mediated 
apoptotic cell death. A A375, RPM-EP, IGR, SK-MEL 28 cells were pre-treated 
with zVAD-fmk (10 μM) or Compound A (100 nM) alone or in combination for 1 h 
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and subsequently stimulated with CD95L (0.5 U/ml) for 18-24 h. Cell viability was 
quantified with crystal violet staining. Summary of three independently performed 
experiments including the S.E.M. of the whole set of experiments is shown. B 
Endogenous expression of respective proteins in human keratinocytes (HaCaT), 
primary melanocytes (Mel #19, Mel #20), nevus cells (Nevus #5 and #8), and 
melanoma cell lines was analysed by western blot. *1 describes an unknown band, 
*2 described an unspecific band. β-tubulin or actin were served as loading control. 
One representative experiment of two independently performed experiments is 
shown. C A375 and IGR cells were stimulated with Compound A (100nM) for 
1hour. cIAP1, cIAP2 and XIAP expression was analysed by western blot. Actin was 
served as loading control. One representative experiment of two independently 
performed experiments is shown. D A375, RPM-EP and IGR melanoma cells were 
either pre-stimulated with zVAD-fmk (10 μM), Nec-1 (50 μM), IAP antagonist (100 
nM) alone or in combinations as indicated for 1 h and subsequently stimulated with 
CD95L (0.5 U/ml) for further 14 h. The externalization of phosphatidylserine as well 
as the amount of death cells were analysed by Annexin V/PI double staining. One 
representative experiment of two independently performed experiments is shown. 
4.1.2 Necroptosis is limited by absence of RIPK3 expression in 
melanoma cells 
The essential role of RIPKs in necroptotic cell death via necrosome assemble has 
been confirmed by recent studies. Since melanoma cells failed to be killed by CD95L 
through necroptotic cell death in vitro, endogenous expression of main necrosome 
components was examined and compared between melanoma cells to primary 
melanocytes, primary nevus cells, and HaCaT keratinocytes. Of interest, RIPK3 
expression was relatively low or absent in melanoma cell lines compared with 
primary melanocytes (Mel #20 but not Mel #19), nevus cells, and HaCaT cells. 
While RIPK1 and MLKL were expressed as normally in most of melanoma cells 
with exception of PREYER, MeWo, and MM-AN cells as in melanocytes, nevus 
cells and HaCaT keratinocytes (Figure 7A). To exclude the possibility that absence 
of RIPK3 in melanomas was unique phenomenon in human, RIPK3 expression in 
five murine melanoma cells lines, which were isolated from two transgenic murine 
melanoma models, were also compared with murine immortalized keratinocytes. 
Consistent with human melanomas, RIPK3 was also low expressed in murine 
melanoma cells, especially in RET model melanoma cell lines (Figure 7A). The 
expression pattern of RIPK3 in melanoma cell lines suggested that absence of RIPK3 
expression was a potential explanation for necroptosis resistance of melanomas. 
To identify if deficiency of RIPK3 in melanomas was mediated by transcription 
repression, its mRNA level was quantified by qPCR. Consistent with western blot 
results, RIPK3 was below detection level in all tested melanoma cell lines. On the 
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contrary, RIPK3 was relatively high expressed in primary melanocytes (Mel #20 but 
not Mel #19), nevus cells, and HaCaT keratinocytes (Figure 7B). Our results 
identified that lack of RIPK3 at transcription level explained the absence of RIPK3 
protein in melanoma. Compared with normal pigmentation cells and keratinocytes, 
RIPK3 was low expressed at mRNA and protein level in human melanoma cell lines, 
which indicated that the deficiency of RIPK3 expression was the potential reason for 
resistance to necroptotic cell death in melanoma cell lines. 
 
Figure 7  Melanoma cell lines are lack of RIPK3 expression in both mRNA and 
protein level. A Endogenous expression of respective proteins of HaCaT 
keratinocytes, primary melanocytes (MEL#19 and MEL #20), nevus cells (Nevus #5 
and #8), and different human and murine melanoma cell lines was analysed by 
western blot. β-tubulin was served as loading control. One representative experiment 
of two independently performed experiments is shown. B Total mRNA from HaCaT 
cells, primary melanocytes, nevus cells, and melanoma cells was isolated and 
reverse transcribed to cDNA. RIPK3 mRNA level was quantified by qPCR. The 
mRNA expression of RIPK3 in melanocytes, nevus cells, and melanomas was 
compared with HaCaT cells that were served as control. Summary of two 
independently performed experiments including the S.E.M. of the whole set of 
experiments is shown. 
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4.1.3 Reconstitution of RIPK3 promotes MLKL phosphorylation 
and allows for CD95L-induced necroptosis in malignant 
melanomas 
Since RIPK3 was low expressed in melanoma cells, the role of RIPK3 and its kinase 
activity on necroptotic cell death in melanomas was subsequently investigated by 
overexpression of RIPK3 or its kinase inactive mutant (RIPK3 D160N) [74] in three 
human melanoma cell lines (A375, IGR, RPM-EP) via retroviral transduction. Of 
interest, successful overexpression of RIPK3 but not its kinase dead mutant led to 
spontaneous phosphorylation of MLKL in all tested melanoma cell lines (Figure 8A). 
This result indicated MLKL, as a part of the necroptosis signalling machinery 
because of RIPK1 and RIPK3 activation, was RIPK3 downstream substrate via 
phosphorylation. 
The role of RIPK3 on cell death was firstly investigated in A375 and IGR melanoma 
cells carrying with RIPK3 overexpression were compared with vector control or 
RIPK3 KD overexpressing cells. Of interest, RIPK3 expression increased melanoma 
cell sensitivity to CD95 ligand, suggesting RIPK3 activity was involved in cell death 
regulation, which was consistent with previous results. Furthermore, whenever the 
expression of cIAPs was depleted by Compound A, cells became more sensitive to 
CD95L induced cell death which was in line with the result of parental cell lines 
(Figure 8B, C). In summary, reconstitution of RIPK3 sensitized A375 and IGR cell 
to CD95L stimulation, which confirmed the regulatory impact on cell death. 
As reconstitution of RIPK3 was sufficient to induce spontaneous phosphorylation of 
MLKL in melanoma cells, effect of RIPK3 on necroptosis regulation was next 
studied. To block caspase-dependent apoptosis, A375 and IGR cells with vector 
control, RIPK3 or RIPK3 KD were pretreated with the caspase inhibitor zVAD-fmk 
for 1 hour. Uniquely in RIPK3 overexpressing melanoma cells, caspase-independent 
necroptotic cell death was remarkably revealed upon CD95L stimulation (Figure 8B, 
C). On the contrary, caspase inhibitor protected vector control or RIPK3 KD 
melanoma cells from CD95L-induced apoptosis as the same as parental melanoma 
cells. In addition, antagonization of IAPs by using Compound A also sensitized 
RIPK3 overexpressing cells to CD95L-mediated necroptosis (Figure 8B, C), which 
verified the inhibitory function of IAPs in necroptosis. These results demonstrated 
the critical function of RIPK3 in melanoma necroptosis. 
In summary, melanoma cells were resistant to necroptotic cell death potentially 
resulting from lack of RIPK3 expression. Reconstitution of RIPK3 via retroviral 
transduction in melanoma cells initiated spontaneous phosphorylation of MLKL and 
subsequently unveiled CD95L-induced necroptosis that can be sensitized by IAP 
antagonist. 
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Figure 8 Overexpression of RIPK3 promotes spontaneous phosphorylation of 
MLKL and CD95L-induced necroptotic cell death. A A375, RPM-EP, and IGR 
cells were transduced with retroviruses containing vector control, cDNA for human 
RIPK3 or its kinase dead mutant (RIPK3 KD). RIPK3 overexpression, as well as for 
p-MLKL, MLKL, RIPK1 were analysed by western blot after transduction and 
selection. β-tubulin was served as loading control. One representative experiment of 
two independently performed experiments is shown. B,C A375 (B) cells or IGR 
cells (C) with expression of vector (control), RIPK3, and RIPK3 KD were 
pre-treated with zVAD-fmk (10 μM) or Compound A (100 nM) alone or in 
combination for 1 h and subsequently stimulated with CD95L (0.5 U/ml) for 18-24 h. 
Cell viability was quantified with crystal violet staining. Summary of three 
independently performed experiments including the S.E.M. of the whole set of 
experiments is shown. 
Reconstitution of RIPK3 could open the door for necroptosis execution in 
melanomas in vitro. For a detailed description of the quantity of the observed cell 
death, the externalization of phosphatidylserine and the change of membrane 
permeability were further investigated in RIPK3 reconstituted melanoma cells by 
Annexin V/PI dual staining followed by FACS analysis and Hoechst/SYTOX® green 
staining by fluorescence intensity analysis. During the process of necroptosis, 
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externalization of phosphatidylserine from inner plasma membrane was confirmed 
by Annexin V staining positivity. In addition, increase of nuclear membrane 
permeability via PI positivity also characterised with necroptosis in RIPK3 
overexpressing melanoma cells (Figure 9A, B).  
 
Figure 9 RIPK3 overexpression promotes CD95L-mediated necroptosis in 
melanoma cells. A375 (A) cells or IGR cells (B) with expression of vector (control), 
RIPK3, and RIPK3 KD were pre-treated with zVAD-fmk (10 μM) or Compound A 
(100 nM) alone or in combination for 1 h and subsequently stimulated with CD95L 
(0.5 U/ml) for 14 h. The externalization of phosphatidylserine as well as the amount 
of dead cells were analysed by FACS following Annexin V/PI staining. One 
representative of two independently performed experiments is shown. C A375 cells 
with respective expressions stimulated as described in A were dual stained with 
Hoechst 3342 and SYTOX® Green followed by fluorescent microscopy analysis. 
One representative experiment of two independently performed experiments is 
shown (L, Light; H, Hoechst3342 staining; S, SYTOX® Green staining). 
Results  37 
 
 
In addition, CD95L-mediated necroptosis was further characterized by Hoechst 3342 
and SYTOX® green staining. In presence of caspase activity, CD95 ligand or in 
combination with IAP antagonist stimulation resulted in apoptosis morphology in all 
cells, including cell shrinkage and condensed nucleus (Figure 9C). While, altered 
cell death morphology was only observed in RIPK3 overexpressing cells whenever 
the activity of caspases was blocked by zVAD-fmk. During necroptotic death, cells 
became rounded shape, accompanying with a swollen cytoplasm and disintegrated 
nuclei (Hoechst 3342 and SYTOX® green dual positivity) (Figure 9C). During the 
process of necroptosis, phosphatidylserine became externalized from the inner 
cellular membrane which was confirmed by the Annexin V staining. Even though 
cells remained intact during the process of necroptosis, the plasma membrane were 
disrupted that enabled big molecules enter into nucleus. The positivity of PI and 
SYTOX® confirmed the increased plasma membrane permeability in the process of 
CD95L-induced necroptosis.  
4.1.4 RIPK3 promotes CD95L-induced necroptosis without altering 
CD95 expression 
The CD95 (also named as Fas, Apo-1) is known as death receptor expressing on cell 
surface to initiate programed cell death. In our study, since reconstitution of RIPK3 
resulted in increased cell sensitivity to CD95 ligand in melanomas in vitro, the 
impact of RIPK3 overexpression on CD95 receptor expression was studied. 
Compared with vector control, receptor surface expression pattern of CD95 was 
unchanged after RIPK3 overexpression both in A375 and IGR cells (Figure 10). 
Reconstitution of RIPK3 in melanoma did not alter surface expression pattern of 
CD95, which excluded the possibility that the increased cell sensitivity to CD95L of 
melanoma cells was related with gain of CD95 surface expression. The other way 
round, without altering death receptor expression, RIPK3 was directly involved in 
programmed cell death and its regulation.  
 
Figure 10 RIPK3 reconstitution does not alter CD95 surface expression. Surface 
expression of CD95 in A375 or IGR cells overexpressing vector or RIPK3 were 
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stained with CD95 specific antibody and quantitatively analysed by flow cytometry. 
Isotype control was used to exclude the unspecific staining of CD95 antibody. One 
representative experiment of two independently performed experiments is shown. 
4.1.5 CD95L-mediated apoptosis and necroptosis in RIPK3 
overexpressing A375 cells are independent of IAP antagonist–
mediated autocrine TNF activation. 
To address the possibility that IAP antagonist induced autocrine TNF production and 
therefore the TNF-dependent cell death signalling in RIPK3 overexpressing cells, the 
recombinant TNFR2-Fc was used to study the TNF dependency in IAP 
antagonist-mediated cell sensitivity in CD95L-induced cell death. Similar with above 
observed results, loss and inhibition of IAPs by Compound A resulted in increasing 
cell sensitivity to both apoptotic and necroptotic death in A375 RIPK3 cells (Figure 
11A). Whereas, in RIPK3-reconstituted A375 melanoma cells, CD95L-induced 
neither apoptosis nor necroptosis was interfered by addition of recombinant 
TNFR2-Fc in presence of IAP antagonist (Figure 11A). The same result was also 
acquired in IGR-RIPK3 cells (data not shown). In addition, Annexin V/PI dual 
staining was used for further qualification and quantification of autocrine 
TNF-dependency in IAP antagonist-induced cell sensitivity. FACS analysis 
demonstrated that recombinant TNFR2-Fc failed to prevent RIPK3 overexpression 
cells from CD95L-mediated apoptosis and necroptosis in presence of Compound A 
which was consistent with crystal violet assay results (Figure 11B). To assure the 
activity of TNFR2-Fc used in our study, HaCaT cells carrying IKK2 kinase mutant 
form (IKK2 KD) which can be killed in TNF-dependent manner were used as 
positive control. Compared with vector control cells, whenever IKK2 kinase was 
mutated in HaCaT, cells became remarkably sensitive to TNF and were blocked by 
addition of recombinant TNFR2-Fc (Figure 11C). These result confirmed the 
bioactivity of our recombinant TNFR2-Fc. 
Taken together, IAP antagonist sensitized RIPK3 overexpressing melanoma cells to 
CD95L-mediated apoptotic and necroptotic cell death, which confirmed the 
inhibitory role of IAPs in programmed cell death. Inability of recombinant 
TNFR2-Fc to protect melanoma cells from death ligand-induced cell death excluded 
the dependency of TNF activation resulted from IAP antagonist in cell sensitivity of 
RIPK3 reconstituted melanomas. 
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Figure 11  CD95L-induced apoptosis and necroptosis in A375-RIPK3 cells are 
independent from Compound A-mediated TNF signalling. A, B A375 cells with 
expression of vector (control), RIPK3, and RIPK3 KD were pre-treated with 
zVAD-fmk (10 μM) or Compound A (100 nM) or TNFR2-Fc (10 mg/ml) alone or in 
combinations for 1 h and subsequently stimulated with CD95L (0.5 U/ml) for 18-24 
h (A) or 14h (C) followed by analysis with crystal violet staining or Annexin V/PI 
staining. Summary of three or two independently performed experiments including 
the S.E.M. of the whole set of experiments is shown. C HaCaT cells with vector 
control or IKK2KD were either non-stimulated or pre-stimulated with TNFR2-Fc 
(10 µg/ml) for 1h and subsequently stimulated with recombinant TNF (10 ng/ml) for 
18-24 hrs followed by crystal violet staining. Summary of two independently 
performed experiments including the S.E.M. of the whole set of experiments is 
shown.  
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4.1.6 Death ligands promote MLKL phosphorylation during the 
process of necroptosis in RIPK3-reconstutide melanoma cells 
During the process of necroptosis, RIPK1 and RIPK3 bind to each other through the 
RHIM domain and further form a amyloid complex where RIPK3 executes 
auto-phosphorylation at its serine 227 residue, which is critical for the interaction 
with MLKL. Upon necroptosis induction, MLKL is recruited to serine 227 
phosphorylated RIPK3 and is subsequently phosphorylated by RIPK3 at the 
threonine 357 and serine 358 residues [157,158].  
In our study, RIPK3 but not its kinase inactive mutant reconstitution led to 
spontaneous phosphorylation at serine 358 residue of MLKL in melanoma cell lines 
(Figure 8A). To further elucidate the role of RIPK3 kinase activity in MLKL 
phosphorylation during necroptosis execution (zVAD-fmk/Compound A/CD95L), 
the status of MLKL phosphorylation was further analysed by western blot. A375 
cells with vector control, RIPK3 or RIPK3 KD were non-stimulated or stimulated 
under necroptotic induction conditions within different time kinetic. The 
phosphorylation of MLKL (Ser358) was increased within 3 hours upon necroptosis 
induction and upregulated in a time-dependent manner exclusively in RIPK3 
overexpressing A375 cells (Figure 12A). In addition, phosphorylation of MLKL was 
also compared between CD95L, TRAIL and TNF. CD95L, led to relatively 
significant phosphorylation of MLKL (Figure 12B). In our study, death ligands of 
TNF superfamily uniquely initiated necroptosis in RIPK3 overexpressing melanoma 
cells. During the process of necroptosis, MLKL was phosphorylated by RIPK3. 
MLKL phosphorylation and subsequent necroptosis execution confirmed the 
indispensable role of RIPK3 and its kinase activity in death ligand-induced 
necroptotic cell death initiation in melanoma cells in vitro. 
 
Figure 12 MLKL is phosphorylated during the death ligand-mediated 
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necroptosis in RIPK3 overexpressing A375 cell. A A375 cells with expression of 
vector (control), RIPK3, and RIPK3 KD were non-treated or pre-treated with 
zVAD-fmk (10 μM) and Compound A (100 nM) in combination for 1 h and 
subsequently stimulated with CD95L (0.5 U/ml) for indicated time. Protein 
expression of p-MLKL (S358), MLKL, RIPK3, RIPK1 and cIAP1 was analysed by 
western blot. β-Tubulin was served as loading control. One representative 
experiment of two independently performed experiments is shown. B A375 cells 
with respective overexpression were non-treated or pre-treated with zVAD-fmk (10 
μM) or Compound A (100 nM) alone or in combination for 1 h and subsequently 
stimulated with CD95L (0.25, 0.5, 1 U/ml), TRAIL (20, 50, 100 ng/ml) or TNF (50, 
100, 200 ng/ml) for 6 hours. Protein expression of p-MLKL (S358), MLKL, RIPK3, 
RIPK1 and cIAP1 was analysed by western blot. Actin was served as loading control. 
One representative experiment of two independently performed experiments is 
shown. 
4.1.7 RIPK1 and RIPK3 kinase activity are determinant for MLKL 
phosphorylation in CD95L induced necroptosis. 
Intriguingly, recent research demonstrated that upon TNF stimulation, RIPK1 and 
RIPK3 form a functional amyloid complex. There consists of RHIM domain of 
RIPKs in the amyloid core, and their kinase domain might flank the core for 
necroptosis signalling transduction [159]. Considering the decisive role of RIPK1 
and RIPK3 playing in necroptosis, the effect of newly reported RIPKs specific 
inhibitors on cell death was scrutinized. The toxicity of RIPKs inhibitors was firstly 
examined in A375 cells. Both RIPK1 and RIPK3 inhibitors exhibited minor toxic or 
proliferation inhibitory effect at the concentration of 10 μM which concentration was 
used for further study (Figure 13A). Notably, RIPK3 specific inhibitors (GSK’840 
and GSK’872) [160,161] pre-treatment remarkably protected RIPK3 overexpressing 
cells from zVAD-fmk/Compound A/CD95L-induced necroptosis, while did not 
influence the apoptotic cell death (Figure 13B). To ascertain that the inhibitory effect 
of RIPK3 inhibitors on necroptosis was via depression RIPK3 kinase activity, the 
phosphorylation of MLKL was next measured by western blot. RIPK3 inhibitors 
down regulated both spontaneous phosphorylation by RIPK3 overexpression and 
CD95L-induced phosphorylation of MLKL (Figure 13C). Compared with RIPK3 
inhibitors, RIPK1 inhibitors (7-Cl-O-Nec-1 and GSK’481) [110,111] and 
Necrostatin-1 (Nec-1) only partially prevented RIPK3 reconstituted A375 cells from 
necroptotic death and did not change the quantity of apoptosis (Figure 13B). Similar 
with RIPK3 inhibitors, the inhibitory effect of RIPK1 inhibitors was related to their 
negative regulatory influence on MLKL phosphorylation (Figure 13C). On the 
contrary, MLKL inhibitor Necrosulfonamide (NSA) was not able to prevent RIPK3 
A375 cells from apoptosis or necroptosis (Figure 13B). Moreover, NSA did not 
demonstrate inhibitory influence on MLKL phosphorylation during necroptosis 
which explained NSA inability on necroptosis protection (Figure 13C). Taken 
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together, in the study of respective necroptosis inhibitors, we found the inhibition of 
respective necroptotic active proteins and necroptosis execution was correlated with 
extent of MLKL phosphorylation. RIPK1, indirectly regulating MLKL 
phosphorylation via interaction with RIPK3 only was only partially involved in 
CD95L-induced necroptosis. In respect of RIPK3, RIPK3 inhibitors completely 
protected melanomas from necroptosis through decrease MLKL phosphorylation. 
Suppressive effect of RIPK3 inhibitors on RIPK3 kinase activity and subsequent 
MLKL phosphorylation, and in turn necroptosis inhibition further affirmed the 
imperative role of RIPK3 in necroptosis execution. 
 
Figure 13 RIPK3 and partially RIPK1 is required for MLKL phosphorylation 
mediated necroptosis. A A375 cells were stimulated with RIPK1 specific inhibitors 
(7-Cl-O-Nec-1 and GSK’481; 10 μM each), RIPK3 specific inhibitors (GSK’840 
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and GSK’872) for 18-24 hours followed by crystal violet staining. Summary of three 
independently performed experiments including the S.E.M. of the whole set of 
experiments is shown. B A375 cells with expression of vector (control), RIPK3, and 
RIPK3 KD were pre-treated with zVAD-fmk (10 μM), Compound A (100 nM),  
RIPK1 specific inhibitors (7-Cl-O-Nec-1 and GSK’481; 10 μM each), Nec-1 (50 
μM), RIPK3 specific inhibitors (GSK’840 and GSK’872) or MLKL inhibitor NSA 
(10 μM) alone or in indicated combinations for 1 h and subsequently stimulated with 
CD95L (0.5 U/ml) for 18-24 hours followed by crystal violet staining. Summary of 
three independently performed experiments including the S.E.M. of the whole set of 
experiments is shown. C A375 cells with expression of vector (control), RIPK3, and 
RIPK3 KD were pre-treated with zVAD-fmk (10 μM), Compound A (100 nM) Nec-1 
(50 μM), RIPK1 specific inhibitors (7-Cl-O-Nec-1 and GSK’481; 10 μM each), 
RIPK3 specific inhibitors (GSK’840 and GSK’872) or NSA (10 μM) alone or in 
indicated combinations for 1 h and subsequently stimulated with CD95L (0.5 U/ml) 
for 6 hours. Protein expression of p-MLKL (Ser358), MLKL, p-ERK, ERK2, RIPK3 
and RIPK1 was analysed by western blot. Actin was served as loading control. One 
of two independently performed experiments is shown. 
4.1.8 Inhibition of RIPK3 kinase activity promotes TNF-complex II 
formation 
Ligation of death ligands to corresponding receptors is able to induce the complex 
assembly in absence of cIAPs activity using IAP antagonists and subsequently 
induce apoptosis or necroptosis [99,100]. Since RIPK3 inhibitors prevented 
RIPK3 reconstituted A375 cells from necroptosis, the effect RIPK3 inhibition on 
caspase 8-bound protein complex formation was analysed via using caspase 8 
antibody coimmunoprecipitation. Upon TNF ligation, FADD, cFLIP, and RIPK1, 
RIPK3, and MLKL were recruited to caspase 8, namely complex II formation. In 
addition, phosphorylated RIPK1 (Ser166) and phosphorylated MLKL (Ser358) 
were also detected in the caspase 8-containing complex (Figure 13). When RIPK3 
kinase activity was suppressed by RIPK3 inhibitor GSK’840, the amount of FADD 
and cFLIP within the complex II were elevated (Figure 13). Furthermore, 
interaction of RIPK3, RIPK1 and p-RIPK1 with caspase 8 were also increased in 
presence of GSK’840 (Figure 13). These results displayed that inhibition of 
RIPK3 activity promoted TNF complex II assembly. On the contrary, MLKL and 
its phosphorylation were less recruited to the complex when RIPK3 activity was 
restrained by GSK’840 (Figure 13).  
Under TNF stimulation, RIPK3 reconstitution uncovered necroptosis through 
MLKL phosphorylation in melanoma cells, while RIPK3 repression by kinase 
inhibitor restrained CD95L-induced necroptosis via downregulating 
phosphorylation of MLKL. In RIPK3 overexpressing A375 cells, TNF-complex II 
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was assembled upon TNF ligation in absence of cIAPs and was locally increased 
by RIPK3 inhibitor (Figure 14). Inhibition of RIPK3 increased TNF complex II 
components interaction with caspase 8 but decrease of MLKL and its 
phosphorylation (Figure 14). These results indicated that Necrosome, which was 
composed of RIPK1, RIPK3 and MLKL, was potential part of complex II and 
dissected from complex II to initiate necroptosis execution. Inhibition of RIPK3 
potentially stabilized TNF-complex II and prevented the necrosome dissociation. 
 
Figure 14 RIPK3 inhibitor increased assembly of TNF-complex II formation. 
A375 RIPK3 overexpressing cells were pretreated with zVAD-fmk (10 μM) and 
Compound A (100 nM) in absence or presence of RIPK3 inhibitor GSK’840 (10 μM) 
for 1 hour and subsequently stimulated with TNF (200 ng/ml) for 4 hours. TNF 
complex II was co-immunoprecipitated from total lysate using caspase 8 antibody 
Respective proteins were subsequently analysed with western blot. One 
representative experiment of two independently performed experiments is shown. 
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4.1.9 DNA-Demethylation by DAC reconstituted RIPK3 expression 
in both human and murine melanoma cells 
DNA methylation is one form of post-transcriptional modifications which add 
methyl groups to cytosine residues of DNA. 5-aza-2’-deoxytidine (Dacogen, DAC), 
as a cytidine analogue, is able to decrease methylation by restricting the activity of 
DNA methyltransferases. Since the mRNA expression level of RIPK3 is low or 
absent in melanoma cell lines, the causality between epigenetic DNA methylation 
and expression silence of RIPK3 was studied with application of demethylation 
reagent DAC. 
Initially, human melanoma cell lines (A375, MM-LH, MM-RU and PM-WK) were 
cultured in medium with 2 μM DAC for four days and the medium with DAC was 
freshened every day. Remarkably, RIPK3 expression was upregulated both at protein 
and mRNA level after demethylation via addition of DAC in human melanoma cells 
(Figure 14A, B). To confirm the general effect of DAC on RIPK3 expression in 
melanoma, murine melanoma cell lines (Ret1, 2 and HcMel3, 12), of which RIPK3 
was also low expressed, were cultured with the same demethylation method as used 
for human melanoma cell lines. Analogously, RIPK3 expression was restored after 
demethylation in murine melanomas cell lines four days after treatment (Figure 14A). 
However unlike ectopical overexpression, reconstitution of RIPK3 via 
demethylation failed to induce spontaneous phosphorylation of MLKL (data not 
shown). In summary, demethylation reagent 5-aza-2’-deoxytidine was able to restore 
RIPK3 expression without altering other necroptosis-related proteins in human and 
murine melanoma cells in vitro, which indicated that hyper methylation was one 
potential mechanism for deficiency of RIPK3 and necroptosis resistance in 
melanomas. 
 
Figure 15 DNA demethylation by 5-aza-2’-deoxytidine (DAC) was able to 
restore RIPK3 expression in melanomas. A Human melanoma cell lines (A375, 
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MM-LH, MM-RU and PM-WK) and murine melanomas cell lines (Ret1, Ret2, 
HcMel3 and HcMel12) were cultured with respective medium containing DAC (2 
μM) and medium with DAC were freshened every day. In the fourth day, cell pellets 
were collected to analyse RIPK3, RIPK1, MLKL, caspase 8 and FADD expression 
by western blot. Actin was served as loading control. One representative experiment 
of two independently performed experiments is shown. B Total mRNA from human 
melanomas cultured as described above was isolated and reverse transcribed to 
cDNA. RIPK3 mRNA was quantified with qPCR. Summary of two independently 
performed experiments including the S.E.M. of the whole set of experiments is 
shown. 
Based on the information available on DBTSS (database of transcription start sites, 
http://dbtss.hgc.jp/), there are predictive CpG islands prone to methylation residing 
in the promoter zone and exon 1 of RIPK3 (Figure 16A). To further certify that the 
methylation status of RIPK3 promoter, two specific primers for methylation specific 
PCR (MSP) as described in methods part were applied to qualification specific locus 
methylation of RIPK3. Compared with control group, DAC treatment decreased the 
methylation of RIPK3 promoter in four human melanoma cell lines (Figure 16B). In 
addition to promoter methylation, methylation was detectable in the region of RIPK3 
exon2 as predicted. In brief, RIPK3 promoter was methylated and its methylation 
was responsible for gene silence. 
In both human and murine melanomas cells, RIPK3 expression was low at the 
transcription level which suggested the potential epigenetic modification in RIPK3 
gene promoter. Addition of demethylation reagent DAC successful restoration 
RIPK3 protein expression without changing RIPK1 and MLKL further indicated that 
methylation was reason for lack of RIPK3 expression. Methylation PCR results 
affirmed the methylation status of RIPK3 gene promoter zone. 
 
Figure 16 RIPK3 promoter is methylated in human melanoma cell lines. A 
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Schematic representation of RIPK3 gene organization. B Human melanoma cells 
(A375, MM-LH, MM-RU and PM-WK) were cultured with respective medium 
containing 5-aza-2’-deoxytidine (2 μM). Medium with DAC were freshened every 
day. In the fourth day, cell pellets were collected for genomic DNA isolation. DNA 
was modified with denaturation and sodium bisulfite treatment based on the protocol 
described in the methods part followed by PCR analysis. Methylation status was 
compared with methylated (M) RIPK3 or unmethylated (U) RIPK3 specific primers. 
One representative experiment of two independently performed experiments is 
shown.  
4.1.10 Demethylation-mediated RIPK3 restoration is not competent 
for necroptosis execution 
Since demethylation was sufficient to recommence RIPK3 expression in melanoma 
cell lines, effect of demethylation-mediated RIPK3 restoration on cell death was 
subsequently investigated. Human melanoma cell lines, of which RIPK3 was 
reconstituted after demethylation treatment, were stimulated under apoptotic 
(CD95L) condition or necroptotic (zVAD-fmk/CD95L) condition in absence or 
presence of IAPs respectively. Of interest, whenever DNA methylation was 
prevented by DAC, metastatic melanoma cells (MM-LH, MM-RU) became more 
sensitive to CD95L-induced apoptosis and further sensitized by IAP antagonist 
(Figure 17). Nonetheless, CD95L failed to induce caspase-independent necroptosis 
in DAC-treated melanoma cells as ineffective as in parental melanoma cells (Figure 
17). In the murine melanoma cells, demethylation-mediated RIPK3 restoration was 
also not sufficient to induce necroptosis (data not shown). 
We found that lack of RIPK3 expression conferred necroptosis resistance in 
melanoma cell lines which was mediate by hyper methylation of RIPK3 promoter. 
Demethylation of RIPK3 by DAC treatment reconstituted its expression without 
altering RIPK1 and MLKL. Although demethylation successfully reconstituted 
RIPK3 in some melanoma cell lines, cells cannot be killed in necroptotic manner. 
Not as strong as ectopic RIPK3 overexpression, demethylation failed to initiate 
MLKL phosphorylation, which can partially explained the incompetence of 
demethylation of RIPK3 in necroptosis induction. In a meanwhile, RPM-EP 
melanoma cells in which RIPK3 was absent were resistant to DAC-mediated 
RIPK3 reconstitution (data not shown). This result suggested potential RIPK3 
mutation and other existed unknown regulatory elements were involved in RIPK3 
expression and in regulation of necroptosis execution in melanomas. 
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Figure 17 Reconstitution of RIPK3 by demethylation is not sufficient to induce 
CD95L-mediated necroptosis. Human melanoma cell lines (A375, MM-LH, 
MM-RU and PM-WK) were cultured with respective medium containing DAC (2 
μM) for four days. Medium with DAC were freshened every day. In the fourth day 
control or DAC treated cells were seeded into 96-well plate. Next day, cells were 
pre-treated with zVAD-fmk (10 μM), Compound A (100 nM) alone or in 
combination for 1 h and subsequently stimulated with CD95L (0.5 U/ml) for 18-24 
hours followed by crystal violet staining. Summary of three independently 
performed experiments is shown including the S.E.M. of the whole set of 
experiments. 
4.1.11 Dabrafenib blocks necroptotic cell death through inhibition 
of RIPK3 kinase activity 
Since activating BRAF mutations account for more than 50 percent of melanoma 
patients, BRAF inhibitors are as an important class of anticancer drugs for melanoma 
targeted therapy [162]. Appealingly, Li, et al. reported that BRAFV600E inhibitor 
Dabrafenib is a potent RIPK3 inhibitor [163]. To investigate the effect of BRAF 
inhibitors effect on different death ligands-induced cell death, melanoma cells 
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carrying with vector control or RIPK3 were pre-treated Dabrafenib. In a meanwhile, 
effect of another BRAF inhibitor Vemurafenib on cell death was also used to 
compare with Dabrafenib. Consistent with reported results, Dabrafenib protected 
RIPK3 overexpressing cells from death ligands-mediated necroptosis but not 
apoptosis in our study (Figure 18A, B). Different from Dabrafenib, Vemurafenib did 
not exhibit any inhibitory impact on necroptosis in melanoma cells (Figure 18A, B). 
Dabrafenib and Vemurafenib, as targeted therapeutic strategy against melanoma 
exhibited significantly clinical effectiveness for melanoma treatment. While 
Dabrafenib but not Vemurafenib protected RIPK3 reconstituted melanoma cells from 
death ligands-induced necroptosis. Considering the off-target effect of Dabrafenib on 
RIPK3 and necroptosis inhibition, Vemurafenib was potentially more promising 
without weakening necroptosis as an alternative form for tumour cell death. 
 
Figure 18 BRAF inhibitor Dabrafenib but not Vemurafenib prevent A375 
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RIPK3 overexpressing cells from death ligand-mediated necroptosis. A375 (A) 
or IGR (B) cells with vector (control) or RIPK3 overexpression were pre-treated 
with zVAD-fmk (10 μM), Compound A (100 nM) alone or in combination in absence 
or presence of respective BRAF inhibitors (10 μM) for 1 h and subsequently 
stimulated with CD95L (0.5 U/ml) or TRAIL (100 ng/ml) or TNF (200 ng/ml) for 
18-24 hours followed by crystal violet staining. Summary of three independently 
performed experiments including the S.E.M. of the whole set of experiments is 
shown. 
Above results confirmed the inhibitory effect of Dabrafenib on necroptosis as 
off-target effect. To further investigate inhibitory function of Dabrafenib in 
necroptosis, phosphorylation of MLKL was next analysed. Both in A375 and IGR 
RIPK3 reconstituted cells, Dabrafenib decreased not only the spontaneous but also 
the necroptosis-induced phosphorylation of MLKL (Figure 19). On the contrary, 
Vemurafenib did not demonstrated inhibitory effect on necroptosis-mediated 
phosphorylation MLKL (Figure 19). These results explained that Dabrafenib 
exercised its inhibitory impact on necroptosis via interfering RIPK3 kinase activity. 
BRAF inhibitor, Dabrafenib but not Vemurafenib, interfered with necroptotic cell 
death through decrease phosphorylation of MLKL through restricting RIPK3 
activity. 
 
Figure 19 Dabrafenib negatively regulated necroptosis via inhibition of 
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RIPK3-mediated spontaneous and CD95L-mediated MLKL phosphorylation. 
A375 or IGR cells with vector (control) or RIPK3 overexpression were pre-treated 
with zVAD-fmk (10 μM), Compound A (100 nM) alone or in combination in 
absence or presence of Dabrafenib (10 μM) or Vemurafenib (10 μM) for 1 h and 
subsequently stimulated with CD95L (0.5 U/ml) for 6 hours.  Expression of 
respective proteins were analysed by western blot. One representative experiment of 
two independently performed experiments is shown. 
Both Dabrafenib and Vemurafenib as BRAF inhibitors are effective target therapies 
against melanoma, while they exhibited different influence on necroptotic cell death. 
Dabrafenib but not Vemurafenib protected RIPK3-reconstituted melanomas from 
death ligands mediated necroptosis. Dabrafenib, sharing the common characteristic 
with RIPK3 inhibitors, exerted its inhibitory impact through restriction of RIPK3 
kinase activity and in turn decreasing phosphorylation of MLKL. 
In this study, the inhibitory role of IAPs in death ligand-induced cell death was 
confirmed by chemical IAP antagonist. Loss and inhibition of IAPs by using IAP 
antagonist increased cell sensitivity, but not promoted melanoma cells from 
apoptosis into necroptosis when caspase activity was repressed. Lack of RIPK3 
expression was identified as the missing link for necroptosis resistance in 
melanomas in vitro. Absence of RIPK3 in melanoma cell lines was the 
consequence of RIPK3 DNA promoter hyper methylation. Ectopical expression of 
RIPK3 unveiled death ligand-induced necroptosis in melanoma cell lines. 
Mutation of RIPK3 kinase domain and addition of RIPK3 specific inhibitors 
further confirmed the indispensability of RIPK3 in necroptosis execution. 
Dabrafenib, which was used as BRAF inhibitor, impaired necroptosis by 
weakening RIPK3 kinase activity which was critical for phosphorylation of 
MLKL and necroptosis execution. Therefore, re-expression of RIPK3, either by 
DNA demethylation or overexpression, can be a strategy for necroptosis based 
therapeutic intervention against melanoma. 
4.2 Identification of NF-κB regulatory effect on melanoma 
cell death 
NF-κB signalling cascade activation initiates transcription of a variety of genes 
including cell death regulators such as cFLIP, Bcl-2 proteins, IAPs [143]. Initially, 
NF-κB activation is considered as negative regulatory signalling for cell death. It 
has been demonstrated by several studies that NF-κB activation is able to inhibit cell 
death induced by distinctive stimuli in a wide variety of cells [143,164]. Therefore, 
disordered NF-κB activation can induce pro-survival and death resistance signalling 
in melanomas in different ways. In this study, the impact of NF-κB activation for 
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cell death regulation in melanoma cells will be studied.  
4.2.1 IKK2 activation leads to constitutive activation of both 
canonical and non-canonical canonical NF-κB pathway 
When the serine 177 and 181 residues of IKK2 are replaced by glutamine (IKK2EE), 
IKK2 became constitutively active resulting in activation of NF-κB pathway. On the 
contrary, IKK2 became dominant negative to block NF-κB pathway if the serine 
residues were mutated with alanine (IKK2 KD) [165]. In order to investigate the 
regulatory effect of NF-κB on cell death in melanoma, stable melanoma cells lines 
overexpressing IKK2 EE or IKK2 KD were generated respectively. Initially, IKK2 
EE was tried to ectopically constitutively expressed, but it resulted in spontaneous 
cell death potentially because of cytokines or chemokines production (data not 
shown). To solve this problem, the overexpression was completed using vectors with 
tamoxifen inducible system. The different mutation forms of IKK2 were also 
transduced to cervical carcinoma HeLa cell to exclude the potential melanoma cell 
line-specific effect. 
Successful overexpression of IKK2 was detectable when cells were stimulated with 
4-hydroxytamoxifen overnight in both melanoma cell lines and HeLa cells. In 
addition, upregulation of p-IκBα also confirmed the NF-κB activation via IKK2 EE 
overexpression (Figure 20). Of interest, canonical NF-κB pathway activation via 
IKK2 EE overexpression, NF-κB2 p100 and its cleavage product p52 were 
upregulated in melanoma and HeLa cells which were usually mediated by IKK1 
activation in non-canonical NF-κB pathway (Figure 20). Consistent with previous 
results that NF-κB activation led to upregulation of a variety of genes that exercise 
anti-apoptotic effect, IKK2 EE overexpression upregulated cFLIP expression in IGR 
and WM1346 cells (Figure 20). In HeLa cells, expression of cFLIPS was increased 
when NF-κB was activated. Furthermore, cIAP1, cIAP2 and A20 which played 
essential but reverse roles in the ubiquitination modification were increased in IKK2 
EE but not IKK2 KD cells (Figure 20). Necroptosis related proteins, RIPK1, RIPK3 
and MLKL were not altered after IKK2 activation. Expression of adaptor protein 
FADD and caspase 8 that were essential for apoptosis was independent from IKK2 
activation status (Figure 20). 
In summary, replacement of serine 177 and 181 residues by glutamine resulted in 
constitutive activation of NF-κB, which was confirmed by phosphorylation and 
degradation of IκBα. In our study, activation of NF-κB by active IKK2 initiated 
expression of a variety of proteins related with cell death resistance, including 
cFLIP, cIAP1, cIAP2 and A20. In addition, overexpression of IKK2 EE resulted in 
upregulation of NF-κB2 p100 and its partial cleavage fragment p52, which 
suggested the potential role of canonical NF-κB in non-canonical NF-κB activation. 
In terms of necroptosis related proteins, NF-κB activation did not display regulatory 
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effect on RIPK1, RIPK3 and MLKL. 
 
Figure 20 IKK2 EE overexpression promotes target genes expression and 
activation of non-canonical NF-κB activation. Human melanoma cell lines (IGR, 
WM1346 and PM-WK) and cervical carcinoma Hele cells were transduced with 
lentiviruses containing vector control, constitutively active IKK2 (IKK2 EE) and 
dominant negative IKK2 (IKK2 KD). After puromycin selection, cells with 
respective vectors were incubated with medium containing 4-hydroxytamoxifen 
(4-HT, 100 nM) overnight. IKK2 overexpression and expression of NF-κB related 
proteins, RIPK1, RIPK3, MLKL, caspase 8, FADD, cFLIP, cIAP1, cIAP2, A20 were 
analysed by western blot. Actin was served as loading control. One representative 
experiment of two independently performed experiments is shown. 
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4.2.2 Constitutive activation of NF-κB renders melanoma cells 
resistance to TNF-mediated apoptosis 
Since overexpression of IKK2 EE resulted in upregulation of proteins that was 
relevant for cell death resistance in melanomas, the role of NF-κB signalling 
machinery on cell death regulation was further investigated. Cell sensitivity to TNF 
was compared between IKK2 EE and vector control or IKK2 KD cells. Consistent 
with the early results from our group [166], expression of dominant negative IKK2 
(IKK2 KD) increased cell sensitivity to TNF stimulation while constitutive IKK2 
activation (IKK2 EE) rendered cell resistance to TNF stimulation in melanoma cells 
in vitro (Figure 21). Moreover, blockade of IAPs by IAP antagonist generally and 
considerably increased cell sensitivity to TNF in melanoma and HeLa cells (Figure 
21). Of interest, IKK2 EE overexpression resulted in acquired spontaneous 
sensitivity to IAP antagonist, which indicated the unusual potential pro-apoptotic 
effect of NF-κB in absence of IAPs (Figure 21). While TNF-mediated cell death in 
absence of IAPs activity was restrained by caspase inhibitor, which excluded that 
NF-κB activation was able to promote necroptosis in melanomas in vitro. 
 
Figure 21 Overexpression of IKK2 EE increase cell resistance to TNF and 
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increased cell sensitivity to IAP antagonist. Melanoma cells (IGR, WM1346 and 
PM-WK) or HeLa cells with expression of vector (control), IKK2 EE, and IKK2 KD 
were incubated with medium containing 4-hydroxytamoxifen (100 nM) overnight. 
Next day, cells were pre-treated with zVAD-fmk (10 μM) or Compound A (100 nM) 
alone or in combination for 1 h and subsequently stimulated with TNF (100 ng/ml) 
overnight followed by crystal violet staining. Summary of three independently 
performed experiments including the S.E.M. of the whole set of experiments is 
shown.  
We found that NF-κB activation resulted in TNF resistance in melanoma cells. On 
the contrary, overexpression of dominant negative IKK2 render cell sensitivity of 
melanoma cells to TNF. These results confirmed the general inhibitory effect of 
NF-κB signalling cascade on melanoma cell death. Moreover, depletion of cIAPs 
and inhibition of XIAP via chemical IAP antagonist led to spontaneous cell death in 
IKK2 active melanoma cells. In summary, NF-κB activated melanoma cells were 
resistant to TNF-mediated cell death but became sensitive to chemical IAP 
antagonist, which suggested the role of NF-κB in cell death regulation potentially 
varied because of the specificity of tested cells. In contrast, both IKK2 EE and IKK2 
KD cells were protected from TNF-induced cell death when caspases activity was 
blocked, which suggested inability of NF-κB to induce necroptosis in melanomas. 
Since activation of IKK2 resulted in spontaneous cell sensitivity to IAP antagonist in 
melanomas, molecular mechanism behind the phenomenon was next studied. As 
transcriptional target genes of NF-κB, both cIAP1 and cIAP2 were upregulated in 
IKK2 EE overexpressing cells. Particularly, cIAP2, which was generally lower 
expressed compared with cIAP1 in melanoma cells, remarkably increased whenever 
NF-κB was activated by inducible IKK2 EE expression (Figure 22). To confirm that 
IAP antagonist-induced cell death in IKK2 EE cells was related with inhibitory 
effect on IAPs, expression of cIAP1 and cIAP2 was compared between vector 
control and IKK2 EE cells in presence of IAP antagonist. As an effective IAP 
antagonist, Compound A was able to decrease both endogenous expression and 
IKK2 EE-mediated upregulation of cIAP1. Although Compound A was sufficient to 
downregulate cIAP2 expression, its inhibitory effect of on NF-κB 
activation-induced cIAP2 was marginal (Figure 22). In addition, a cleavage product 
of caspase 8, oligomerized p18 fragment was uniquely detectable in IKK2 EE 
overexpressing cells upon IAP antagonist treatment. Furthermore, NF-κB2 p52 was 
accumulated when cIAP1 was depleted in WM1346 cells. 
Although NF-κB played negative role in TNF-mediated apoptosis in melanomas, 
activation of NF-κB by constitutively active IKK2 led to spontaneous cell death 
when IAPs activity was impaired by IAP antagonist. This unexpected pro-apoptotic 
impact of NF-κB on melanoma was completed through downregulate cIAP1 and 
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slightly cIAP2 by addition of Compound A. Moreover, an active fragment of 
caspase-8 p18 was only detectable in IKK2 EE cells by IAP antagonist stimulation. 
These results confirmed the pro-apoptotic effect of IKK2 activation in melanoma 
cells in absence of IAPs activity. 
 
Figure 22 IAP antagonist decreases cIAP1 and slightly cIAP2 and promotes 
caspase 8 cleavage to induce apoptosis. IGR and WM1346 melanoma cells with 
expression of vector (control) or IKK2 EE, were treated with 4-HT (100 nM) 
overnight to induce gene of interest to express. Next day, cells were treatd by 
Compound A (100 nM) for 1 h. Total lysate was isolated and respective proteins 
were analysed by western blot. One representative experiment of two independently 
performed experiments is shown. 
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4.2.3 Spontaneous apoptosis of IKK2 EE cells in absence of IAPs 
was independent from IAP antagonist-mediated autocrine 
TNF activation 
Since IAP antagonist was sufficient to induce apoptosis in IKK2 EE cells, 
dependency of IAP antagonist-mediated TNF activation was investigated to unmask 
the molecular mechanism behind the cell death. TNF mRNA expression was firstly 
compared between vector control cells and IKK2 EE overexpressing cells in absence 
of IAP antagonist. As a target gene of NF-κB signalling cascade, TNF was increased 
considerably in IKK2 EE cells compared with vector control. When cIAP1 was 
depleted by Compound A, TNF was marginally increased in mRNA level in the 
IKK2 EE IGR cells (Figure 23A).  
 
Figure 23 IAP antagonist-induced apoptosis is independent from IAP 
antagonist-mediated autocrine TNF activation in IKK2 EE IGR cells. A Vector 
control or IKK2 EE overexpressing IGR cells were non-stimulated or stimulated 
with Compound A (100 nM) for 1 hour. Total mRNA was isolated and reverse 
transcribed to cDNA. TNF level was quantified with qPCR. Summary of two 
independently performed experiments including the S.E.M of the whole set of 
experiments is shown. B Vector control or IKK2 EE overexpressing IGR cells were 
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pre-treated with recombinant TNFR2-Fc (10 μg/ml) for 1 h and subsequently 
stimulated with compound A (100 nM) overnight followed by crystal violet staining. 
Summary of three independently performed experiments is shown including the 
S.E.M. of the whole set of experiments. C IGR cells were transfected with either 
siCTRL or siTNFR1 for 48 h. Knockdown effect was quantified with TNFR1 mRNA 
qPCR analysis. Summary of two independently performed experiments is shown 
including the S.E.M of whole set of experiments. D Vector control or IKK2 EE 
overexpressing IGR cells were transfected with either siCTRL or siTNFR1 for 48 h 
and subsequently stimulated with compound A (100 nM) overnight followed by 
crystal violet staining. Summary of three independently performed experiments 
including the S.E.M. of the whole set of experiments is shown. 
To further investigate if this minor upregulation of endogenous TNF by IAP 
antagonist was sufficient to induce apoptosis in IKK2 EE cells sensitivity, 
recombinant TNFR2-Fc was used to block the TNF signalling machinery to confirm 
the effect of IAP antagonist-induced TNF. Interestingly, addition of TNFR2-Fc 
failed to prevent IKK2 EE cells from compound A-mediated cell death (Figure 23B). 
To further conclude that apoptosis resulting from loss of cIAP1 in IKK2 EE cells was 
independent from IAP antagonist-mediated autocrine TNF loop, siRNA of TNFR1 
were used to downregulate TNFR1 expression. The knockdown efficiency of 
TNFR1 was confirmed by qPCR analysis (Figure 23C). Consistently with addition 
of TNFR2-Fc, knockdown of TNFR1 expression was not sufficient to block 
Compound A-induced cell death in IKK2 EE overexpression cells (Figure 23D).  
In this part of study, NF-κB activation resulted in increase of TNF expression at 
mRNA level that was slightly increased after IAPs inhibition. Blockade of TNF 
signalling by addition of recombinant TNFR2-Fc failed to protect IKK2 EE cells 
from IAP antagonist-induced apoptosis suggest the independency of autocrine TNF 
activation by IAP antagonist in IKK2 EE cell death, knockdown of TNFR1 was also 
incompetent to prevent IKK2 EE cells from apoptosis in absence of IAPs. These 
results demonstrated that the pro-apoptotic effect of IKK2 activation was 
independent from IAP antagonist-mediated autocrine TNF activation. 
4.2.4 Loss of cIAP1 promotes formation of RIPK1-dependent 
Ripoptosome to induce apoptosis by constitutive NF-κB 
activation 
It has been confirmed by early results from our group that cIAPs are negative 
regulators for Ripoptosome formation [99]. To identify the role of loss of cIAPs in 
apoptosis in IGR IKK2 EE cells, the proteins interacting with caspase 8 were 
immunoprecipitated following Compound A stimulation and compared with vector 
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control cells. Of interest, loss of cIAP1 by Compound A stimulation resulted in 
recruitment of FADD, cFLIP, RIPK1 to caspase 8 in NF-κB inducibly activated IGR 
cells by addition of 4-HT (Figure 24). These results suggested that decrease of 
cIAP1 by IAP antagonist was sufficient to induce Ripoptosome formation without 
exogenous ligands stimulation when NF-κB was activated. In addition, 
phosphorylated RIPK1, which was difficult to detect in the total lysate samples, was 
massively recruited to the Ripoptosome complex (Figure 24). These results 
indicated that RIPK1 especially its phosphorylation was functionally relevant for 
IAP antagonist-induced cell death in IKK2 EE cells.  
NF-κB activation resulted in cIAP1 and cIAP2 expression and inhibition of cIAPs 
mainly cIAP1 by IAP antagonist led to spontaneous apoptotic cell death in IGR 
IKK2EE cells. Assembly of Ripoptosome potentially explained the IAP 
antagonist-induced apoptosis in IKK2 EE melanoma cells. In the complex, 
phosphorylated RIPK1 was recruited substantially which suggested the 
indispensable role of RIPK1 in apoptosis of IKK2 EE cell in absence of cIAPs. 
 
Figure 24 Loss of cIAP1 promotes Ripoptosome formation in IKK2 EE cells. 
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IGR cells with overexpression of vector (control) or IKK2 EE, were treated with 
4-HT (100 nM) to induce expression of gene of interest overnight followed by 
Compound A (100 nM) stimulation for 1 h. Caspase 8 was immunoprecipitated from 
total cell lysates (Input) as described in the methods part. Respective co-precipitated 
proteins were analysed by western blot. One representative experiment of two 
independently performed experiments is shown. 
Considerable recruitment of RIPK1 and RIK1 phosphorylation in the Ripoptosome 
complex led us to investigate the dependency of RIPK1 in IAP antagonist-mediated 
cell death in IKK2 EE cells (Figure 25A). Compared with vector control, IKK2 
constitutive activation leads to spontaneous sensitivity to IAP antagonist which was 
consistent with previous results. Of interest, RIPK1 inhibitor, Necrostatin-1, largely 
rescued IKK2 EE cells from cell death. To further confirm the essential role of 
RIPK1 for cell death in IKK2 EE cells, the role of RIPK1 in Ripoptosome formation 
was also investigated. As expected, level of FADD and cFLIP recruited to caspase 8 
was decreased, namely repression of RIPK1 decreased Ripoptosome formation. 
Significantly, RIPK1 and its phosphorylation were both downregulated when RIPK1 
kinase activity was restrained by its inhibitor (Figure 25B). 
In brief, during the study of RIPK1 dependency in IKK2 EE cells apoptosis in 
absence of cIAPs, we found that RIPK1 activity was required for the cell death. 
RIPK1 was phosphorylated and recruited to the Ripoptosome complex and further 
induced IAP antagonist-mediated cell death in IKK2 EE melanoma cells. 
In summary, NF-κB activation initiates a variety of genes transcription, including 
cell death-related proteins. In this study, we confirmed that NF-κB activation 
resulted in upregulation of IAPs and cFLIP which rendered melanoma resistance to 
TNF-mediated apoptosis. Inhibition of IAPs via IAP antagonist increased cell 
sensitivity to TNF stimulation in vitro. Different from the general inhibitory impact 
of NF-κB on cell death, depletion of cIAPs resulted in spontaneous cell death when 
NF-κB was activated via inducible expression of constructively active IKK2. IAP 
antagonist-induced apoptosis in IKK2 EE IGR cells was independent from the IAP 
antagonist-mediated autocrine-TNF activation. The pro-apoptosis effect of IKK2 
activation on IAP antagonist-induced cell death was result of RIPK1-dependent 
Ripoptosome assembly. These results suggested that the pro-survival NF-κB 
signalling can also transverse into pro-apoptotic cell cascade under specific 
conditions like IAPs depletion in melanoma cell lines.   
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Figure 25 IAP antagonist-mediated Ripoptosome assembly and apoptosis in 
IKK2 EE overexpressing cells is RIPK1 dependent. A IGR cells with 
overexpression of vector (control) or IKK2 EE, were treated with 4-HT (100 nM) 
overnight to induce expression of gene of interest. Next day, cells were pretreated 
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with zVAD-fmk (10 μM), or TNFR2-Fc (100 ng/ml) or Necrostatin-1(10 μM) alone 
or in combination and subsequently stimulated with Compound A (100 nM) 
stimulation overnight followed by crystal violet staining. Summary of three 
independently performed experiments including the S.E.M. of the whole set of 
experiments is shown. B IGR IKK2EE cells were treated with 4-HT (100 nM) 
overnight to induce expression of gene of interest. Next day, cells were pretreated 
with zVAD-fmk (10 μM) for 1 hour followed by Compound A (100 nM) stimulation 
for 4 hours. Caspase 8-bound proteins were immunoprecipitated from total cell 
lysates (Input) by caspase 8 specific antibody. Expression of respective 
co-precipitated proteins was analysed by western blot. One representative 
experiment of two independently performed experiments is shown.
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5. Discussion 
5.1 IAPs inhibits CD95L-mediated cell death in melanoma 
Melanoma is primarily resistant or acquires resistance to targeted therapeutics such 
as BRAF inhibitors or in combination with MEK inhibitors [167]. It is worth of 
investigations to ascertain the resistance mechanism of melanomas and better 
increase sensitivity to therapeutics and prolong the survival rate of melanoma 
patients. 
In our study, the cell sensitivity to CD95 ligand (CD95L) of human melanoma cell 
lines from different stages was studied. A375 and RPM-EP cells are originated from 
primary or recurrent primary cutaneous melanoma, while IGR cells are from lymph 
node metastasis and SK-MEL 28 cells are from subcutaneous metastasis of 
melanoma. Compared with primary melanomas, metastatic cell lines were more 
resistant to CD95 ligand-mediated apoptosis (Figure 6A) which was consistent 
previous results [168] reported by our lab. Moreover, in RIPK3 reconstituted cells, 
the metastatic cell line (IGR) was also less sensitive to CD95L-mediated necroptosis 
compared with A375 RIPK3 cells (Figure 8B, C). These results suggested that 
melanoma cells have gained the resistance in the process of metastasis and the extent 
of metastasis were probably relevant for the cellular resistance. 
For further understanding of the cell death resistance mechanisms in melanoma, the 
role of IAPs was studied because of their well-characterized inhibition in regulation 
of caspases and RIPK1 activities and in turn cell death. An impressive finding was 
that cIAP1 was uniformly expressed in different stages of melanomas as 
keratinocytes, melanocytes and nevus cells. In contrast, cIAP2 was only expressed 
in A375, RPM-EP melanoma cells and HaCaT keratinocytes. Of interest, the level of 
XIAP expression was higher in melanoma than keratinocytes, melanocytes or nevus 
cells (Figure 6B). Therefore, cIAP1 and XIAP could play the main role of cell death 
resistance and inhibition of these proteins might represent a promising strategy for 
melanoma treatment. The IAP antagonist, Compound A, used in this study is 
designed to disrupt the function of XIAP and downregulate the endogenous 
expression of cIAP1 and cIAP2 [120]. In terms of inhibitory effect, the protein level 
of cIAP1 can be downregulated by Compound A with lower concentration in A375 
cells than IGR cells. Compared with cIAP2, the effect of Compound A on cIAP1 was 
more specific in A375 cells (Figure 6C). 
Even though apoptosis and necroptosis regulated the cell death via utilization of 
different signalling machineries [43], considerably increased cell sensitivity to 
CD95L-mediated both apoptosis (Figure 6A, D) and necroptosis (Figure 8B, C) was 
detected when IAP activity was suppressed by Compound A in all tested melanoma 
cells. These results evidently demonstrated that cIAP1 and XIAP conferred main 
resistance to CD95L-induced cell death and suggested the less indispensable role of 
cIAP2 in cell death resistance. As well, early reports of our group confirmed that the 
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anti-apoptotic effect of cIAP1 was more distinguishable than cIAP2 [166]. In IGR 
cells which lack of XIAP and cIAP2 expression, Compound A increased its cell 
sensitivity through downregulation of cIAP1. To ascertain which proteins have more 
significant regulatory impact on cell death, it has to be noted that the expression 
level of IAP family members varies among different stages and types of cell lines. It 
is also reported that IAP antagonist is able to increase the efficiency of radiology in 
prostate cancer treatment [169] and sensitivity to chemotherapy in glioblastoma 
[170]. In all, inhibition of IAPs sensitizes melanoma cells to CD95L-mediated cell 
death. Therefore, a combination of IAP inhibition and death receptor activation 
could be an effective strategy for elimination of melanoma tumours in patients. 
5.2 RIPK3 is lost during the development of melanoma 
because of promoter methylation 
When melanoma cell sensitivity to CD95L was screened, it was found that human 
melanomas were killed by CD95L in an exclusively apoptotic manner (Figure 6A, 
C). Lack of caspases-independent and RIPKs-dependent necroptosis makes it 
intriguing to unveil the mechanism of necroptosis resistance in human melanomas. 
Gene deficient mouse models have confirmed that loss of certain components of 
necroptosis machinery, especially RIPK3 and MLKL, usually protects different 
tissues or mice from necroptotic cell death [171-173]. Of interest, compared with 
normal pigmentation cells and keratinocytes, RIPK3，but not MLKL, was absent in 
melanoma cells (Figure 7A, B) in our study, which suggested that absence of RIPK3 
could be a potential reason for lack of in vitro necroptosis in melanomas. In addition 
to human melanomas, RIPK3 expression level was also low in melanoma cell lines 
derived from the transgenic melanoma mice (Figure 7A). 
In human melanomas, absence of RIPK3 protein expression is a consequence of lack 
of RIPK3 expression at transcriptional level (Figure 7B). A general lack of RIPK3 
mRNA can be a result of limited promoter activation controlled by epigenetic 
modifications such as DNA methylation and histone deacetylation. In both human 
and murine melanoma cells, demethylation reagent 5-aza-2’-deoxytidine 
tremendously restored expression of RIPK3 without influencing expression of other 
cell death related proteins (Figure 15A). Within the availability of genetic 
information of RIPK3, CpG islands near the RIPK3 transcription start site (TSS) 
were identified in a variety of human tissue and cancer cells 
(http://dbtss.hgc.jp/#chr14:24335619-24341040:-). Methylation specific PCR (MSP) 
results verified methylation of RIPK3 promoter and the methylation of RIPK3 was 
reversible through addition of demethylation reagent 5-aza-2’-deoxytidine (Figure 
16B). Furthermore, methylation level of RIPK3 promoter was decreased more 
significantly in primary melanoma cell lines (A375 and PM-WK) than in the 
metastatic melanoma cells (MM-RU and MM-LH) after demethylation ( B). On the 
contrary, in human RPM-EP melanoma cells, 5-aza-2’-deoxytidine was not able to 
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upregulate RIPK3 expression (data not shown). In murine melanomas, although 
RIPK3 expression was restored in all murine melanoma cells in vitro, melanoma cell 
lines originated from DMBA-induced HGF-CDK4R24C-transgenic melanoma mice 
were more sensitive to 5-aza-2’-deoxytidine-induced demethylation than cells from 
RFP-RET-transgenic mice (Figure 15A). Koo G.B, et al. recently reported that about 
two thirds of sixty cancer cell lines representing different types and stages of cancers 
abnormally express RIPK3 as undetectable level including glioblastoma, lung 
adenocarcinoma, hepatocellular carcinoma, bladder transitional cell carcinoma, 
breast ductal carcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, and 
pancreatic adenocarcinoma, prostate adenocarcinoma [154]. In contrast, in terms of 
cancer cell lines originated from hematopoietic malignancies including acute 
lymphoblastic T leukaemia, acute myeloid leukaemia, acute monocytic leukaemia, 
Burkitt’s B-cell lymphoma and follicular B cell lymphoma, the expression of RIPK3 
is detectable. In summary, RIPK3 is low expressed in a panel of cancer cell lines as 
well as melanoma and its expression can be reconstituted by demethylation reagent. 
However, inconsistent expression level and response to demethylation of RIPK3 in 
melanoma and other cancers cell lines suggest that promoter methylation only can 
partially explains the silence of RIPK3 and other unknown mechanisms such as gene 
mutations are required further investigations. 
Of interest, DAC treatment increased apoptotic cell sensitivity to CD95L in MM-LH 
and MM-RU cells (Figure 17), which was potentially related with upregulation of 
RIPK3 since its facilitative regulatory in apoptosis independent from kinase activity. 
In the meanwhile, other tumour suppressor genes also restored after demethylation 
in melanoma.  
Although demethylation treatment restored RIPK3 expression to detectable level 
and increased cell sensitivity to CD95L-mediated apoptosis, it failed to induce 
CD95L-mediated necroptosis in absence of caspase 8 activity (Figure 17). Unlike 
RIPK3 overexpressing cells, demethylation of RIPK3 was unable to induce 
spontaneous phosphorylation of MLKL. Furthermore, phosphorylated MLKL was 
undetectable under necroptotic induction conditions in demethylated melanoma 
cells (data not shown). These results suggested demethylation was sufficient to 
reconstitute RIPK3 expression but insufficient to rescue its kinase activity. Given 
cells that are resistant to demethylation like RPM-EP, it is quite probable that the 
other unknown mechanisms exist to regulate RIPK3 expression and its kinase 
activity.  
In contrast with CD95 ligand, both Doxorubicin and Etoposide, as common 
chemotherapeutics for cancers, are able to induce RIPK3-dependent necroptosis in 
5-aza-2’-deoxytidine treated cancer cells [154]. Doxorubicin and Etoposide, as DNA 
damage reagents, interfere with the process of DNA transcription and generally 
induce apoptosis via mitochondria-mediated pathway. In the earliest researches for 
necroptosis, it is believed that mitochondria are required for the induction of 
necroptosis [174,175]. Recent evidence casts doubt on the idea that the involvement 
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of mitochondria is essential in necroptotic signalling machinery [102,176,177]. The 
involvement of mitochondria and its related cell death effectors in necroptosis 
induction need further experiment proof. In addition to RIPK3 kinase activity, it has 
been demonstrated by several groups that the interaction between RIPK3 and HSP90 
is required for RIPK3 activation and necroptosis induction [178,179]. On the other 
hand, demethylation reagents decreased the lysine methylation of Hsp90 [180]. Is 
the effect of demethylation on HSP90 interfere its interaction with RIPK3 needed 
further experimental proof. These results indicate that ectopical expression of 
RIPK3 differs from its natural expression because of potential lack of post 
translational scaffold or modifications. If RIPK3 only performs as a kinase or may 
also involves in the stoichiometry modulation of proteins within death-inducing 
complexes by a presumed scaffold function is an intriguing question that needs to be 
addressed by further studies. 
5.3 RIPK3 kinase and partial RIPK1 activity is critical for 
MLKL phosphorylation and necroptosis initiation 
Previous studies have revealed that RIPK3 is imperative in necroptotic cell death 
regulation during embryonic development [181,182], inflammation [172,183,184], 
virus infections [185] and cell death upon different stimuli ligation [76,84,99,186]. 
In our study, RIPK3 but not its kinase inactive mutant ectopical expression allowed 
for necroptotic cell death which was absent in the parental melanoma cells. Unlike 
RIPK3, RIPK1 generally was expressed in all the tested melanoma cell lines and its 
expression and phosphorylation were not altered by RIPK3 overexpression (Figure 
7A and Figure 8A). These results indicated that RIPK3 but not RIPK1 expression as 
a kinase was the missing link for necroptosis initiation in human melanoma.  
Although RIPK1 and RIPK3 share common characteristics in structure, RIPK1 
possesses an unique C-terminal death domain (DD) for interaction with other 
proteins containing DD. RIPK1 is recruited to plasma membrane associated complex 
I upon death ligand ligation and dissected into cytoplasm as a secondary complex 
when it is deubiquitinated. In the cytoplasmic complex, RIPK1 interacts with RIPK3 
as an amyloid-like structure followed by phosphorylation [74]. Within the complex, 
RIPK1 is auto-phosphorylated at the serine 166 residue that positively contributes to 
RIPK1 activation and interaction with RIPK3. Auto-phosphorylation at Ser227 
residue of RIPK3 is not required for RIPK1/RIPK3 necrosome assembly, but 
essential for the interaction of RIPK3 with MLKL [157]. When RIPK1 activity was 
blocked by its inhibitors, CD95L/IAP antagonist-induced necroptosis was only 
partially protected in our study. While in case of RIPK3 repression, necroptotic cell 
death under the same stimuli conditions were completely rescued by addition of 
RIPK3 specific inhibitors (Figure 13). These results suggested that RIPK1 inhibitors 
disrupted interaction between RIPK1 and RIPK3, in turn resulting in decrease of 
RIPK3 in the necrosome complex but without affecting its kinase activity. If the 
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remaining less RIPK3 in the complex is still able to induce necroptosis, this 
hypothesis needs to be proved by further RIPK1 co-immunoprecipitation.  
To date, there is still lack of discriminative biochemical biomarkers for the in situ 
detection of necroptosis in vitro and in vivo. MLKL is firstly discovered to be 
involved in necroptosis as searching RIPK3 interacting proteins by using 
necroptosis inhibitor Necrosulfonamide (NSA) and later confirmed by siRNA 
library [102]. MLKL interchanges with phosphorylated RIPK3 through its 
C-terminal pseudokinase domain upon necroptosis induction. Following recruitment, 
MLKL is phosphorylated by RIPK3 at Thr357 and Ser358 residues. In our study, the 
overexpression of RIPK3 but not its kinase mutant led to the spontaneous 
phosphorylation (Ser358) of MLKL as strong as it in HaCaT keratinocytes in which 
RIPK3 was expressed normally (Figure 8A). The basal phosphorylation of MLKL in 
RIPK3 overexpressing cells and HaCaT keratinocytes have not led to spontaneous 
necroptosis, suggesting phosphorylation of MLKL is an essential but not decisive 
step of necroptosis induction. Phosphorylation of MLKL is believed to induce a 
conformational change as releasing the N-terminal four-helix bundle domain of 
MLKL which is indispensable for necroptosis induction. Murphy, et al. found that 
structure-guided mutation of the MLKL pseudo-active site resulted in constitutive, 
RIPK3 independent necroptosis, indicating that modiﬁcations of MLKL is required 
for initiation of the necroptosis pathway downstream of RIPK1/RIPK3 platform 
[102]. Even though reconstitution of RIPK3 leads to spontaneous MLKL 
phosphorylation, it is still not sufficient to induce conformational change compared 
with the level under necroptotic stimuli conditions. Furthermore, development and 
application of RIPK1 and RIPK3 inhibitors enable to further prove the role of RIPKs 
in necroptosis. In our study, RIPKs inhibitors, especially RIPK3 inhibitors, 
prevented MLKL from phosphorylation (Figure 13B, C). The extent of MLKL 
phosphorylation is relevant for the percentage of necroptotic cell death which 
demonstrates that MLKL phosphorylation by RIPK3 is required in the necroptosis. 
MLKL is characterized with an N-terminal coiled-coil domain region and a 
C-terminal kinase-like domain that is responsible for binding to RIPK3. NSA 
competitively binds to the cysteine 86 in the N-terminal coiled-coil domain of 
MLKL instead of C-terminal pseudokinase domain [157]. Not as effective as RIPKs 
inhibitors, NSA is unable to decrease MLKL phosphorylation or CD95L-mediated 
necroptosis in RIPK3 overexpressing melanoma cells in vitro (Figure 13B, C). 
Structural studies of MLKL identified the Lys219 and Glu343 as functionally 
indispensable residues for ATP binding of murine MLKL. Site mutations of these 
two residues (K219M and Q343A) in murine MLKL result in its constitutive 
activation and necroptosis without stimuli [102]. These principles support our 
finding that NSA is not sufficient to block CD95L-mediated necroptosis. 
In addition to RIPK3 specific inhibitors, Li, et al. found that six different BRAF 
inhibitors, Dabrafenib as the most potent one, selectively inhibited RIPK3 kinase 
activity by competitively binding to its ATP site [163]. In our study, the described 
68  Discussion 
off-target effect of Dabrafenib protected RIPK3-reconstituted melanoma cells from 
not only necroptotic cell death via inhibition of RIPK3 kinase activity (Figure 18, 
19). In addition to hindrance of RIPK3 activity, other unknown molecules involved 
in cell signalling regulation such as MAPK are potentially influenced by Dabrafenib. 
On the contrary, alternative BRAF inhibitor Vemurafenib failed to suppress MLKL 
phosphorylation and necroptosis (Figure 18, 19). The distinctive effect of these two 
BRAF inhibitors on necroptosis raises further attention to investigate the interaction 
between BRAF/MAPK mediated proliferation signalling and RIPK3-mediated 
necroptosis. In terms of therapeutic intervention, the off-target effect of Dabrafenib 
on cell death mainly on necroptosis should be considered. Since Dabrafenib 
interferes with the necroptosis via impairing RIPK3 kinase activity, it is not suitable 
for using it in combined therapy.  
5.4 Constitutively active IKK2 EE renders cell resistance to 
TNF stimulation via expression of anti-apoptotic proteins 
in melanoma cells 
The first member of the nuclear factor-kappa B (NF-κB) protein family was 
discovered in 1988. As a family consisted of transcription factor, NF-κB activation 
leads to a wide variety of genes transcription. According to their functions, target 
genes of NF-κB can be categorized into cytokines/chemokines and their modulators, 
immunoreceptors, proteins involved in antigen presentation, cell adhesion 
molecules, acute phase proteins, stress-related proteins, cell surface receptors, cell 
death regulators, growth factors and their modulators, transcription factors and their 
modulators, enzymes [164].  
Since the main focus of this study is the regulatory effect of NF-κB on melanoma 
cell death, stable melanoma cell lines with IKK2 mutations that imitate the 
constitutively active (IKK2 EE) or dominant negative (IKK2 KD) forms of IKK2 
were respectively generated. Initially, IKK2 EE was tried to be ectopically 
constitutively expressed, but it resulted in spontaneous cell death potentially because 
of cytokines or chemokines production (data not shown). To solve this problem, the 
overexpression was completed using vectors with tamoxifen inducible system. 
Consistent with previous results, successful IKK2 EE overexpression led to the 
phosphorylation and degradation of IκBα and further the activation of NF-κB 
signalling machinery (Figure 20). Unlike the canonical NF-κB pathway, activation 
of NIK (NF-κB-inducing kinase) only requires activation of IKK1, not IKK2 nor 
NEMO, for leading to phosphorylation and processing of NF-κB2 p100 into p52 
[187]. In our study, only IKK2 activation led to upregulation of both precursor 
NF-κB2 p100 and its partial degradation product p52 (Figure 20). It is known that 
activation of NF-κB initiates the expression of NF-κB2 in a feedback regulatory 
circuit [188]. In case of NF-κB2 p52, since the expression level of NIK was not 
altered after IKK2 activation (data not shown), if active IKK2 was sufficient to 
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mediate the processing of NF-κB2 p100 or active IKK2 inter-phosphorylated IKK1 
resulting in processing of NF-κB2 p100 needed further studies. More and more 
studies have recognised that canonical and non-canonical NF-κB pathways are not 
completely independent from each other. 
In respect of transcriptional function, NF-κB activation resulted in anti-apoptotic 
protein expression as previous reported (Figure 20). Both the long and short form of 
cFLIP, a natural inhibitor of caspase 8, was significantly upregulated in IGR and 
WM1346 cells after IKK2 activation. However, in PM-WK cells and HeLa cells, the 
level of cFLIP was not altered significantly post IKK2 activation, which indicated 
the transcriptional regulatory effect of NF-κB on cFLIP was cell specific (Figure 20). 
In addition, both cIAP1 and cIAP2 were upregulated in IKK2 active cells (Figure 
20). cIAP2 is weakly detectable in most cancer cells including melanomas because 
of its shorter half-life than cIAP1, which might be due to an increased susceptibility 
of cIAP2 to spontaneously dimerize, auto-ubiquitinate, and be degraded [122]. 
Whenever NF-κB was activated, cIAP2 increased remarkably especially in cells that 
were lack of cIAP2 expression, in turn which suggested cIAP2 played critical role in 
NF-κB activation (Figure 20). In terms of the ubiquitin-editing enzyme A20, its 
expression was also elevated by NF-κB activation in all the tested cells regardless of 
its endogenous expression level. One additional band about 70 kDa was detected and 
upregulated consistent with the expression pattern of the band near 100 kDa in IKK2 
EE cells (Figure 20). Further experiments are needed to confirm the specificity of 
the lower molecular weight band. A20 is capable of terminating NF-κB activation 
through degradation of Lys63-linked poly-ubiquitin chains on RIPK1 as a 
deubiquitinase and further proteasomal degradation of RIPK1 by addition of 
Lys48-linked poly-ubiquitin chains as an ubiquitin E3 ligase [189]. Hutti JE, et al. 
reported IKK2 activation phosphorylates A20 at its Ser381 residue to increase its 
inhibitory effect on NF-κB activation [190]. In our study, even though A20 was 
recruited after NF-κB activation, the inhibitory feedback of A20 was not dominant, 
potentially because of its modification by IKK2 activation. For the necroptosis 
related proteins, RIPK1, RIPK3 and MLKL, none of them was changed after IKK2 
activation (Figure 20). RIPK3 which was absent in melanoma and HeLa cells was 
still low expressed, which excluded the possibility that NF-κB activation was 
required for RIPK3 expression and partially explained the incompetence of NF-κB 
activation to induce necroptosis. 
Since NF-κB activation enabled the upregulation of anti-apoptotic proteins 
expression, the negative regulatory effect of NF-κB on apoptosis was studied. 
Cancer cells are generally resistant to TNF because of intrinsical activation of 
NF-κB. Both vector control and IKK2 EE cells have not responded to TNF 
stimulation (Figure 21). On the contrary, consistent with previous results that 
IKK2 inactivation rendered cell sensitivity to TNF [166], melanoma cells 
overexpressing IKK2 KD became sensitive to TNF (Figure 21). Moreover, when 
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activity of IAPs was blocked by Compound A, cells became sensitive to TNF, 
which was because of autocrine TNF-loop induced by IAP antagonist [120]. On 
the contrary, IAP antagonist-induced apoptosis in IKK2 EE cells were 
independent from IAP-mediated autocrine TNF activation (Figure 23B, D). In 
addition, either melanoma cells or HeLa cells were lack of RIPK3 expression, 
TNF or TNF/IAP antagonist solely induced caspase-dependent cell death (Figure 
21). When NF-κB was activated by constitutive IKK2, cells, lack of RIPK3 
expression, were still resistant to necroptosis in presence of IAP antagonist. 
NF-κB activation initiates a variety of genes transcription but not RIPK3, which 
partially explained the inability of NF-κB for necroptosis induction. In addition, 
NF-κB activation crosstalks with other pro-survival signalling which potentially 
antagonize necroptosis machinery. The regulatory effect of NF-κB on necroptosis 
needed to be further studied within cells that RIPK3 expressed normally like 
HaCaT keratinocytes. 
5.5 Constitutive activation of IKK2 promotes melanoma cell 
death in absence of cIAP1 independent from IAP 
antagonist-mediated autocrine TNF activation 
When cIAPs were depleted by IAP antagonist, spontaneous cell sensitivity was 
observed in all tested IKK2 active melanoma cells (Figure 21). As effective as in 
parental cells, Compound A was able to decrease the endogenous and inducible 
expression of cIAP1 to the undetectable level (Figure 22). In respect of cIAP2, 
compound A exhibited less efficient inhibition especially for the NF-κB 
activation-induced cIAP2. cIAP2, which expression level was low in melanomas, 
was enhanced by IKK2 activation and remained stable in spite of IAP antagonist 
treatment. The less responsive reaction of cIAP2 to Compound A can be explained 
by resistance of its homodimers to Smac mimetics-induced degradation and its 
characteristic of rapid induction by NF-κB [121,122]. These results demonstrated 
that NF-κB activation mainly induced cIAP2 expression, while Compound A 
exercised its cell death induction effect principally through depleting cIAP1 
instead of cIAP2 expression. Caspase activation is central to the regulation of 
apoptotic pathways. In the process of IAP antagonist-mediated apoptosis, the 
initiator caspase 8 was cleaved and activated as p18 fragment that was consistent 
with the function of other IAP antagonist in various cancer cells (Figure 22). 
Because of the inhibitory effect of cIAPs on NIK, addition of IAP antagonist 
releases NIK into the cytoplasm and promotes the partial degradation of NF-κB2 
p100 into p52. Consistent with the known knowledge, IAP antagonist increased 
the processing of the precursor NF-κB2 p100 into p52 fragment (Figure 22). 
It has been confirmed by continuous studies that IAP antagonist is capable of 
inducing apoptosis in TNF-dependent manner in sensitive cells [120,191]. 
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Activation of NF-κB induces a variety of genes transcription including TNFα, 
CD95L and TRAIL, IAP antagonist-mediated cell death only can be rescued by 
TNFR1-Fc [120]. Inconsistent with this general TNF-dependency in IAP 
antagonist-mediated apoptosis, neither addition of recombinant TNFR2-Fc or 
knockdown of TNFR1 by siRNA failed to protect IKK2 EE cells from IAP 
antagonist-induced apoptosis (Figure 23B, D). Unlike IAP antagonist-mediated 
NF-κB activation, active IKK2 EE led to more forceful and durable NF-κB 
activation. In turn the amount of cytokine production was more considerable 
(Figure 23A). When death ligands interact with respective receptors, the 
signalling commences within complexes formation at the plasma membrane and 
matures to generate cytoplasmic secondary signalling complexes, which appears 
to occur not only for TNFR1 but also Fas, TRAILR and TLR [99,153,192,193]. In 
previous project, the inhibitory effect of recombinant TNFR2-Fc on 
TNF-mediated apoptosis was confirmed in IKK2 KD HaCaT and melanoma cells. 
Failure of suppression of TNFR2 to protect IKK2 EE cells from compound 
A-induced apoptosis suggested the potential existence of other death platforms 
which were independent from TNF production. Even though TNFR1 siRNA 
decreased TNF receptor expression, there still remained considerable level of 
TNFR1. To exclude or confirm the TNF-dependency in IAP antagonist apoptosis, 
further experiments are needed, such as generation of TNFR1 knockout cell lines 
by CRISPR, blockade of Fas or TRAIL receptors by its relative antibodies. 
5.6 Loss of cIAP1 promotes RIPK1-dependent Ripoptosome 
formation in IKK2 active melanoma cells 
In the absence of survival signalling, membrane associated TNF complex I 
transits to cytoplasm as complex IIa, which mainly contains TRAF2, FADD, 
caspase 8, and RIPK1, to induce apoptosis. It has been proved loss of cIAP1 
promotes the other form of complex assembly in absence of death receptor 
stimulation, known as Ripoptosome [80,99,153]. In our study, depletion of cIAP1 
and downregulate cIAP2 expression led to the spontaneous Ripoptosome complex 
formation without exogenous death ligands stimulation in IKK2 EE cells. The 
components of the complex included caspase 8, p-RIPK1 (Ser166), RIPK1, 
FADD, cFLIP (long, short and p43 forms), and A20 (Figure 24). In terms of the 
composition of the TNF complex IIa and Ripoptosome, there are no substantial 
differences. However, the stimuli of both complexes are certainly different. 
Unlike TNF-induced complex II, Ripoptosome formation can be triggered in the 
absence of TNF signalling [99,100]. In our study, IAP antagonist promoted 
complex formation in IKK2 EE cells. Although it did not require extra exogenous 
TNFα or other TNF family death ligands, IKK2 activation itself resulted in 
considerable accumulation of endogenous production of TNF and other death 
ligands. Inability of TNFR2-Fc to protect IKK2 EE cells from IAP 
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antagonist-mediated cell death suggested the possibility that loss of cIAP1 in 
IKK2 EE cells advocated the Ripoptosome not TNF complex II assembly. TNFR1 
knockout or inhibition of the TNF signalling can be used to confirm the identity of 
the complex. 
RIPK1 dependency for its Ripoptosome formation was substantiated by addition 
of RIK1 inhibitor Necrostatin-1 (Figure 25B). Upon TNFα stimulation, RIPK1 
was immediately ubiquitinated with K63 poly-ubiquitin chains that can be 
degraded and converted into K48 poly-ubiquitin chains by A20 [189]. In addition 
to ubiquitination, phosphorylation of RIPK1 is required for its effect on both 
apoptosis and necroptosis. In our study, blockade of RIPK1 kinase activity 
prevented IKK2 EE cells from IAP antagonist-mediated cell death (Figure 25A). 
Similar with many kinases, auto-phosphorylation of RIPK1 plays a critical role in 
its activation. RIPK1 is auto-phosphorylated on the Ser161 residue. Of interest, 
point mutations (S161A and S161E/D) of RIPK1 that predict the conformational 
change of the RIPK1 T-loop disable the Necrostain-1 to inhibit RIPK1, suggesting 
that Nec-1 is an allosteric inhibitor of RIP1 kinase. X-ray crystallography study 
confirms that Nec-1 binds to a hydrophobic pocket between the N- and C-lobes of 
the kinase domain and stabilizes RIPK1 in an inactive conformation [194,195]. In 
NF-κB constitutively active melanoma cells, Necrostatin-1 partially protected 
cells from apoptotic cell death resulting from IAP antagonist. Moreover 
phosphorylation of RIPK1 found in the cytoplasmic complex in response to the 
IAP antagonist is also decreased because of RIPK1 inhibition. Phosphorylation of 
RIPK1 is required for its interaction with RIPK1 for necroptosis. However these 
results indicated RIPK1 kinase activity was required for auto-phosphorylation and 
apoptosis induction in IKK2 EE cells. 
In summary, inhibitors of apoptosis proteins, which were regulated by NF-κB 
activation, rendered resistance to death ligand-induced cell death in melanoma 
cells in vitro (Figure 26). Inhibition of IAPs by IAP antagonist sensitized 
melanoma cells to death ligand-mediated apoptosis. In addition, when NF-κB was 
activated, IAP antagonist was sufficient to induce Ripoptosome formation and 
subsequent apoptosis which were RIPK1 dependent (Figure 26). Either death 
ligands or IAP antagonist exclusively induced caspase-dependent apoptosis but 
not RIPKs-dependent necroptosis in melanoma cell lines. Necroptosis resistance 
of melanoma cells resulted from lack of RIPK3 expression of which DNA 
promoter was hyper methylated. Moreover, demethylation reagent restored 
RIPK3 expression in melanomas but not sufficient to initiate necroptosis. 
Ectopical expression of RIPK3 via retroviral transduction in melanoma cell lines 
initiated necroptosis execution through phosphorylation of MLKL (Figure 26). 
Better understanding of cell death regulation in melanomas provides theoretical 
basis for melanoma clinical treatment. 
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Figure 26 Identification of RIPK3 and NF-κB for melanoma cell death 
regulation 
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Abbreviations 
% Percent 
°C Degree Celsius 
μ Micro  
4-HT 4-hydroxytamoxifen  
APAF1 Apoptotic protease-activating factor 1 
Bak Bcl-2 antagonist or killer 
Bax Bcl-2-associated X protein 
Bcl-2 B-cell lymphoma 2 
BH3 Bcl-2 homology 3 
Bid BH3 interacting-domain death agonist 
BIR baculovirus inhibitor repeat 
BSA Bovine serum albumin 
C Cysteine 
C10 Caspase 10 
C8 Caspase 8 
CAD Caspase-activated DNase 
CD40L Cluster of differentiation 40 ligand 
CD95L Cluster of differentiation 95 ligand 
cFLIP Cellular FLICE-like inhibitory protein 
cIAPs Cellular inhibitor of apoptosis proteins 
CRD Cysteine-rich domain 
CTRL Control 
d Days 
DD Death domain 
DED Death effector domain 
DISC Death-inducing signalling complex 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleoside triphosphate 
Doxy Doxycycline 
EDTA Ethylenediaminetetraacetic acid 
ERK Extracellular-signal-regulated kinase 
FADD Fas-associated protein with death domain 
FCS Fetal Bovine serum 
FLICE FADD-like IL-1β-converting enzyme 
g Gramm 
GAPDH Glyceraldehyde 3-phosophate dehydrogenase 
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h Hour 
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid 
IKK IκB kinase 
IL-8 Interleukin-8 
HPCE high-performance capillary electrophoresis 
HPLC high-precision liquid chromatography 
JNK c-Jun N-terminal kinase 
kDa Kilo Dalton 
l Liter 
LB Lysogeny broth 
m Milli 
M Molarity 
MAPK Mitogen-activated protein kinases 
min Minute 
MLKL Mixed lineage kinase domain-like 
MOMP Mitochondrial outer membrane permeabilization 
n Nano 
n.s. Not significant 
Nec-1 Necrostatin-1 
Necrosulfonamide  NSA 
NEMO NF-κB-essential modulator 
NF-κB Nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells 
NIK NF-κB-inducing kinase 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PI Propidium iodide 
PVDF Polyvinylidene difluoride 
RIPK Receptor-interacting protein kinase 
RNA Ribunucleic acid 
RT Room temperature 
Ser Serine 
siRNA Small interfering RNA 
SMAC Second mitochondria-derived activator ofcaspases 
TAB1 TAK1 binding protein 1 
TAK1 Transforming growth factor β-activated kinase 1 
tBid Truncated Bid 
TL Total cell lysate 
TLR Toll-like receptor 
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Tm Melting temperature 
TNF Tumor necrosis factor 
TNFAIP3/A20 TNFα-induced protein3 
TNF-R2 TNF receptor 2 
TRADD TNF receptor type 1-associated death domain protein 
TRAF2 TNF receptor-associated factor 2 
TRAIL TNF-related apoptosis inducing ligand 
TRAIL-R TRAIL receptor 
TWEAK TNF-related weak inducer of apoptosis 
UV Ultra violet 
V Volt 
v/v Volume per volume 
w/v Weight per volume 
x G Gravitational acceleration 
XIAP X-linked inhibitor of apoptosis protein 
zVAD-fmk z-Val-Ala-DL-Asp-fluoromethylketone 
 
